SUSAN G KOMEN BREAST CANCER FOUNDATION: Form 990, tax year 2021

View the entire original 990 at ProPublica ↗

Organization: SUSAN G KOMEN BREAST CANCER FOUNDATION (EIN 75-1835298)
Tax period: 2021-04-01 to 2022-03-31
Filed: 2023-01-18
IRS object ID: 202310189349301001
Schema version: 2021v4.2
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule M
Schedule O

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2023-01-18T16:30:12+00:00	ReturnTs
Tax Period End	2022-03-31	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Field	Value	IRS element (for citing)
Preparer Firm EIN	346565596	PreparerFirmEIN

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	ERNST & YOUNG US LLP	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	1901 SIXTH AVENUE NORTH SUITE 1200	AddressLine1Txt
City	BIRMINGHAM	CityNm
State Abbreviation	AL	StateAbbreviationCd
ZIP	35203	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2021-04-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	751835298	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	The Susan G Komen Breast Cancer Foundation Inc	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Business Name Control	SUSA	BusinessNameControlTxt
Phone	9728551600	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	13770 NOEL ROAD SUITE 801889	AddressLine1Txt
City	DALLAS	CityNm
State Abbreviation	TX	StateAbbreviationCd
ZIP	75380	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	PAULA SUE SCHNEIDER	PersonNm
Person Title	PRESIDENT AND CEO	PersonTitleTxt
Signature	2023-01-18	SignatureDt
Discuss With Paid Preparer	Yes (true)	DiscussWithPaidPreparerInd

Signing Officer SigningOfficerGrp

Person Full Name PersonFullName

Field	Value	IRS element (for citing)
Person First	PAULA SUE	PersonFirstNm
Person Last	SCHNEIDER	PersonLastNm

Field	Value	IRS element (for citing)
SSN	999009999	SSN

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	Kathy Pitts	PreparerPersonNm
PTIN	P00292940	PTIN
Phone	2052512000	PhoneNum

Field	Value	IRS element (for citing)
Tax	2021	TaxYr
Build TS	2023-03-07 01:45:13Z	BuildTS

Form 990 IRS990

Doing Business As Name DoingBusinessAsName

Field	Value	IRS element (for citing)
Business Name Line1	SUSAN G KOMEN	BusinessNameLine1Txt

Principal Ofcr Business Name PrincipalOfcrBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	PAULA SUE SCHNEIDER	BusinessNameLine1Txt

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	13770 NOEL ROAD SUITE 801889	AddressLine1Txt
City	DALLAS	CityNm
State Abbreviation	TX	StateAbbreviationCd
ZIP	75380	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$165,642,733	GrossReceiptsAmt
Group Return For Affiliates	false	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	WWW.KOMEN.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	1982	FormationYr
Legal Domicile State	TX	LegalDomicileStateCd
Activity Or Mission	OUR MISSION IS TO SAVE LIVES BY MEETING THE MOST CRITICAL NEEDS IN OUR COMMUNITIES AND INVESTING IN BREAK-THROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER.	ActivityOrMissionDesc
Voting Members Governing Body	18	VotingMembersGoverningBodyCnt
Voting Members Independent	18	VotingMembersIndependentCnt
Total Employee	556	TotalEmployeeCnt
Total Volunteers	1456	TotalVolunteersCnt
Total Gross UBI	$10,933	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$0	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$50,983,746	PYContributionsGrantsAmt
CY Contributions Grants	$99,456,148	CYContributionsGrantsAmt
PY Program Service Revenue	$3,259,501	PYProgramServiceRevenueAmt
CY Program Service Revenue	$2,500	CYProgramServiceRevenueAmt
PY Investment Income	$7,389,057	PYInvestmentIncomeAmt
CY Investment Income	$7,437,450	CYInvestmentIncomeAmt
PY Other Revenue	$26,113,354	PYOtherRevenueAmt
CY Other Revenue	$4,365,358	CYOtherRevenueAmt
PY Total Revenue	$87,745,658	PYTotalRevenueAmt
CY Total Revenue	$111,261,456	CYTotalRevenueAmt
PY Grants And Similar Paid	$15,229,334	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$25,691,669	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$27,327,944	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$36,149,496	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$1,158,758	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$1,181,706	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$22,781,842	CYTotalFundraisingExpenseAmt
PY Other Expenses	$31,051,187	PYOtherExpensesAmt
CY Other Expenses	$37,609,513	CYOtherExpensesAmt
PY Total Expenses	$74,767,223	PYTotalExpensesAmt
CY Total Expenses	$100,632,384	CYTotalExpensesAmt
PY Revenues Less Expenses	$12,978,435	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	$10,629,072	CYRevenuesLessExpensesAmt
Total Assets BOY	$193,189,248	TotalAssetsBOYAmt
Total Assets EOY	$207,354,061	TotalAssetsEOYAmt
Total Liabilities BOY	$55,926,370	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$59,717,916	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$137,262,878	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$147,636,145	NetAssetsOrFundBalancesEOYAmt
Mission	Komen's mission is to save lives by meeting the most critical needs in our communities and investing in breakthrough research to prevent and cure breast cancer.	MissionDesc
Significant New Program Srvc	false	SignificantNewProgramSrvcInd
Significant Change	false	SignificantChangeInd
Expense	$40,955,788	ExpenseAmt
Grant	$4,503,337	GrantAmt
Revenue	-$5,448	RevenueAmt
Desc	PATIENT CARE AND ADVOCACY: PROVISION OF BREAST CANCER SCREENING, DIAGNOSIS, AND TREATMENT PROGRAMS THROUGH GRANTS TO OTHER NON-PROFIT ORGANIZATIONS, THIRD-PARTY CONTRACTS AND DIRECTLY BY KOMEN, WITH A SPECIAL EMPHASIS ON PATIENT NAVIGATION, ESPECIALLY IN COMMUNITIES WHERE DISPARITIES IN OUTCOMES ARE SIGNIFICANT AND/OR ACCESS IS LIMITED. SEE SCHEDULE O FOR ADDITIONAL DETAILS.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$24,901,656	ExpenseAmt
Grant	$21,181,617	GrantAmt
Revenue	$2,500	RevenueAmt
Desc	GRANTS TO RESEARCH INSTITUTIONS AND OTHER NONPROFIT ORGANIZATIONS TO SUPPORT BREAST CANCER RESEARCH PROJECTS INCLUDING THOSE FOCUSED ON THE BIOLOGY OF BREAST CANCER; NEW STRATEGIES TO TREAT, DETECT, AND PREDICT RISK OF BREAST CANCER, AND UNDERSTANDING AND ADDRESSING DISPARITIES IN OUTCOMES. SEE SCHEDULE O FOR ADDITIONAL DETAILS.	Desc

Field	Value	IRS element (for citing)
Total Program Service Expenses	$65,857,444	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (true)	DescribedInSection501c3Ind
Schedule B Required	Yes (true)	ScheduleBRequiredInd
Political Campaign Acty	false	PoliticalCampaignActyInd
Lobbying Activities	Yes (true)	LobbyingActivitiesInd
Donor Advised Fund	false	DonorAdvisedFundInd
Conservation Easements	false	ConservationEasementsInd
Collections Of Art	false	CollectionsOfArtInd
Credit Counseling	false	CreditCounselingInd
Donor Rstr Or Quasi Endowments	Yes (true)	DonorRstrOrQuasiEndowmentsInd
Report Land Building Equipment	Yes (true)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	Yes (true)	ReportInvestmentsOtherSecInd
Report Program Related Invst	false	ReportProgramRelatedInvstInd
Report Other Assets	false	ReportOtherAssetsInd
Report Other Liabilities	false	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (true)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	false	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	Yes (true)	ConsolidatedAuditFinclStmtInd
School Operating	false	SchoolOperatingInd
Foreign Office	false	ForeignOfficeInd
Foreign Activities	Yes (true)	ForeignActivitiesInd
More Than5000 K To Org	Yes (true)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	false	MoreThan5000KToIndividualsInd
Professional Fundraising	Yes (true)	ProfessionalFundraisingInd
Fundraising Activities	Yes (true)	FundraisingActivitiesInd
Gaming Activities	false	GamingActivitiesInd
Operate Hospital	false	OperateHospitalInd
Grants To Organizations	Yes (true)	GrantsToOrganizationsInd
Grants To Individuals	Yes (true)	GrantsToIndividualsInd
Schedule J Required	Yes (true)	ScheduleJRequiredInd
Tax Exempt Bonds	false	TaxExemptBondsInd
Engaged In Excess Benefit Trans	false	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	false	PYExcessBenefitTransInd
Loan Outstanding	false	LoanOutstandingInd
Grant To Related Person	false	GrantToRelatedPersonInd
Business Rln With Org Mem	false	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	false	BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent	false	BusinessRlnWith35CtrlEntInd
Deductible Non Cash Contri	Yes (true)	DeductibleNonCashContriInd
Deductible Art Contribution	false	DeductibleArtContributionInd
Terminate Operations	false	TerminateOperationsInd
Partial Liquidation	false	PartialLiquidationInd
Disregarded Entity	false	DisregardedEntityInd
Related Entity	false	RelatedEntityInd
Related Organization Ctrl Ent	false	RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	false	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	false	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (true)	ScheduleORequiredInd
IRP Document	133	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (true)	BackupWthldComplianceInd
Employee	556	EmployeeCnt
Employment Tax Returns Filed	Yes (true)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	Yes (true)	UnrelatedBusIncmOverLimitInd
Form990 T Filed	Yes (true)	Form990TFiledInd
Foreign Financial Account	false	ForeignFinancialAccountInd
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTransInd
Taxable Party Notification	false	TaxablePartyNotificationInd
Nondeductible Contributions	false	NondeductibleContributionsInd
Quid Pro Quo Contributions	Yes (true)	QuidProQuoContributionsInd
Quid Pro Quo Contri Discl	Yes (true)	QuidProQuoContriDisclInd
Form8282 Property Disposed Of	Yes (true)	Form8282PropertyDisposedOfInd
Form8282 Filed	1	Form8282FiledCnt
Rcv Fnds To Pay Prsnl Bnft Cntrct	false	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	false	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	false	IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt	false	SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc	false	SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	18	GoverningBodyVotingMembersCnt
Independent Voting Member	18	IndependentVotingMemberCnt
Family Or Business Rln	false	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	false	DelegationOfMgmtDutiesInd
Change To Org Documents	false	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	false	MaterialDiversionOrMisuseInd
Members Or Stockholders	false	MembersOrStockholdersInd
Election Of Board Members	false	ElectionOfBoardMembersInd
Decisions Subject To Approva	false	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (true)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (true)	MinutesOfCommitteesInd
Officer Mailing Address	false	OfficerMailingAddressInd
Local Chapters	Yes (true)	LocalChaptersInd
Policies Reference Chapters	Yes (true)	PoliciesReferenceChaptersInd
Form990 Provided To Gvrn Body	Yes (true)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (true)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (true)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (true)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (true)	WhistleblowerPolicyInd
Document Retention Policy	Yes (true)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (true)	CompensationProcessCEOInd
Compensation Process Other	Yes (true)	CompensationProcessOtherInd
Investment In Joint Venture	false	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	DC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	GA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	HI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ME	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MO	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	ND	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AZ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
Own Website	Yes (X)	OwnWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RIA WILLIAMS	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Phone	9728551600	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	13770 NOEL ROAD SUITE 801889	AddressLine1Txt
City	DALLAS	CityNm
State Abbreviation	TX	StateAbbreviationCd
ZIP	75380	ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (34 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd	Former Ofcr Director TrusteeFormerOfcrDirectorTrusteeInd
Ed Dandridge
Chair of the Board (BEG Jun 2021 )	1.0	0	Yes (X)	Yes (X)	$0	$0	$0
Jerri Johnson
BOD Member (Vice Chair BEG Mar 2021	1.0	0	Yes (X)	Yes (X)	$0	$0	$0
Andi Owen
BOD Member (BEG Mar 2021)	1.0	0	Yes (X)		$0	$0	$0
BJ Schaknowski
BOD Member (BEG Mar 2022)	1.0	0	Yes (X)		$0	$0	$0
Christina Minnis
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Eugene Kim
BOD Member (END Mar 2022)	1.0	0	Yes (X)		$0	$0	$0
Gail Heimann
BOD Member (BEG Mar 2021)	1.0	0	Yes (X)		$0	$0	$0
John O'Neill
BOD Member	1.0	0	Yes (X)		$0	$0	$0
Julia Harris
BOD Member (BEG Mar 2021)	1.0	0	Yes (X)		$0	$0	$0
Julie Gruber
BOD Member (BEG Mar 2022)	1.0	0	Yes (X)		$0	$0	$0
Kristen Racich
BOD Member (BEG Mar 2022)	1.0	0	Yes (X)		$0	$0	$0
Kwanza Jones
BOD Member (END Mar 2022)	1.0	0	Yes (X)		$0	$0	$0
Luke Sauter
BOD Member (BEG Mar 2021)	1.0	0	Yes (X)		$0	$0	$0
Lydia The
BOD Member (BEG Mar 2022)	1.0	0	Yes (X)		$0	$0	$0
Michelle Bottomley
BOD Member (BEG Mar 2021)	1.0	0	Yes (X)		$0	$0	$0
Peter D Brundage
BOD Member (frmr Chair, Chair end Jun 2021)	1.0	0	Yes (X)		$0	$0	$0
Renee Baker
BOD Member (BEG Mar 2021)	1.0	0	Yes (X)		$0	$0	$0
Robyn Shepherd
BOD Member (BEG Mar 2022)	1.0	0	Yes (X)		$0	$0	$0
Sean Slovenski
BOD Member (BEG Mar 2021)	1.0	0	Yes (X)		$0	$0	$0
Susannah Gray
BOD Member (END Mar 2022)	1.0	0	Yes (X)		$0	$0	$0
Traci Blunt
BOD Member (BEG Mar 2021)	1.0	0	Yes (X)		$0	$0	$0
Dana Brown
Chief Operating Officer	55.0	0		Yes (X)	$465,537	$0	$15,637
Eunice Nakamura
General Counsel & Corporate Secretary	55.0	0		Yes (X)	$269,473	$0	$14,336
Paula Schneider
President and CEO	55.0	0		Yes (X)	$682,520	$0	$31,412
Ria Williams
Chief Financial Officer	55.0	0		Yes (X)	$290,183	$0	$21,782
Catherine Olivieri
SVP, Human Resources	55.0	0			$289,457	$0	$22,580	Yes (X)
Lori Maris
SVP, Ops Services & Support	55.0	0			$243,277	$0	$12,596	Yes (X)
Victoria Wolodzko
SVP, Mission	55.0	0			$340,267	$0	$9,729	Yes (X)
Kari Bodell
VP, Dev Progs Strat	55.0	0			$229,605	$0	$7,955		Yes (X)
Kimberly Sabelko
VP, Sci Strat & Programs	55.0	0			$202,212	$0	$15,723		Yes (X)
Michelle Strong
VP, Marketing Strat	55.0	0			$225,607	$0	$13,095		Yes (X)
Sarah Rosales
VP, Corp Partnerships	55.0	0			$233,478	$0	$16,798		Yes (X)
Srinivasu Avadhanula
VP, BI Platfm & Eng	55.0	0			$241,720	$0	$7,910		Yes (X)
Kimberly Johnson
Former Sr. Director AAHEI		0.0			$182,424	$0	$1,769			Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$3,895,760	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$191,322	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	92	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	false	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (true)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	false	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (5 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt
Event 360
205 N Michigan Ave	Chicago	IL	60601	Event Management	$2,349,796
RKD Group LLC
3400 Waterview Parkway	Richardson	TX	75080	Consulting	$1,086,596
CSM Sport & Entertainment Inc
8770 Guion Road	Indianapolis	IN	46268	Consulting	$458,250
Ernst & Young
3712 Solutions Center	Chicago	IL	60677	Acctg & Tax Services	$329,983
MSB Financial Solutions LLC
79 Cherrywood Dr	Nashua	NH	03062	Consulting	$323,309

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	20	CntrctRcvdGreaterThan100KCnt
Federated Campaigns	$262,529	FederatedCampaignsAmt
Membership Dues	$0	MembershipDuesAmt
Fundraising	$25,041,236	FundraisingAmt
Related Organizations	$0	RelatedOrganizationsAmt
Government Grants	$4,527,545	GovernmentGrantsAmt
All Other Contributions	$69,624,838	AllOtherContributionsAmt
Noncash Contributions	$182,327	NoncashContributionsAmt
Total Contributions	$99,456,148	TotalContributionsAmt

Program Service Revenue ProgramServiceRevenueGrp (5 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt	Unrelated Business RevenueUnrelatedBusinessRevenueAmt	ExclusionExclusionAmt
Affiliate Treatment Assistance Fund	900099	$2,500	$2,500	$0	$0
		$0	$0	$0	$0
		$0	$0	$0	$0
		$0	$0	$0	$0
		$0	$0	$0	$0

Total Oth Program Service Rev TotalOthProgramServiceRevGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$0	ExclusionAmt

Field	Value	IRS element (for citing)
Total Program Service Revenue	$2,500	TotalProgramServiceRevenueAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$1,152,853	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$1,152,853	ExclusionAmt

Incm From Invest Bond Proceeds IncmFromInvestBondProceedsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$0	ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$3,507	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$3,507	ExclusionAmt

Gross Rents GrossRentsGrp

Field	Value	IRS element (for citing)
Real	$0	RealAmt
Personal	$0	PersonalAmt

Less Rental Expenses LessRentalExpensesGrp

Field	Value	IRS element (for citing)
Real	$0	RealAmt
Personal	$0	PersonalAmt

Rental Income Or Loss RentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Real	$0	RealAmt
Personal	$0	PersonalAmt

Net Rental Income Or Loss NetRentalIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$0	ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Securities	$56,458,504	SecuritiesAmt
Other	$0	OtherAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Securities	$50,173,907	SecuritiesAmt
Other	$0	OtherAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Securities	$6,284,597	SecuritiesAmt
Other	$0	OtherAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$6,284,597	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$6,284,597	ExclusionAmt

Field	Value	IRS element (for citing)
Fundraising Gross Income	$977,618	FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event	$25,041,236	ContriRptFundraisingEventAmt
Fundraising Direct Expenses	$4,150,957	FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$3,173,339	TotalRevenueColumnAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	-$3,173,339	ExclusionAmt

Field	Value	IRS element (for citing)
Gaming Gross Income	$4,642	GamingGrossIncomeAmt
Gaming Direct Expenses	$31,204	GamingDirectExpensesAmt

Net Income From Gaming NetIncomeFromGamingGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$26,562	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	-$26,562	ExclusionAmt

Field	Value	IRS element (for citing)
Gross Sales Of Inventory	$14,061	GrossSalesOfInventoryAmt
Cost Of Goods Sold	$25,209	CostOfGoodsSoldAmt

Net Income Or Loss NetIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$11,148	TotalRevenueColumnAmt
Related Or Exempt Func Income	-$11,148	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$0	ExclusionAmt

Other Revenue Misc OtherRevenueMiscGrp (3 entries)

DescDesc	BusinessBusinessCd	Total Revenue ColumnTotalRevenueColumnAmt	Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt	Unrelated Business RevenueUnrelatedBusinessRevenueAmt	ExclusionExclusionAmt
SHARED SERVICES	900099	$5,700	$5,700	$0	$0
OTHER INCOME	900099	$3,574	$0	$10,933	-$7,359
MERGER RELATED INCOME	900099	$7,563,626	$0	$0	$7,563,626

Miscellaneous Revenue MiscellaneousRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$0	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	$0	ExclusionAmt

Field	Value	IRS element (for citing)
Other Revenue Total	$7,572,900	OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$111,261,456	TotalRevenueColumnAmt
Related Or Exempt Func Income	-$2,948	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$10,933	UnrelatedBusinessRevenueAmt
Exclusion	$11,797,323	ExclusionAmt

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$21,294,309	TotalAmt
Program Services	$21,294,309	ProgramServicesAmt

Grants To Domestic Individuals GrantsToDomesticIndividualsGrp

Field	Value	IRS element (for citing)
Total	$3,829,950	TotalAmt
Program Services	$3,829,950	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$567,410	TotalAmt
Program Services	$567,410	ProgramServicesAmt

Benefits To Members BenefitsToMembersGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$2,708,786	TotalAmt
Program Services	$1,405,372	ProgramServicesAmt
Management And General	$658,068	ManagementAndGeneralAmt
Fundraising	$645,346	FundraisingAmt

Comp Disqual Persons CompDisqualPersonsGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$28,161,837	TotalAmt
Program Services	$14,624,022	ProgramServicesAmt
Management And General	$6,764,699	ManagementAndGeneralAmt
Fundraising	$6,773,116	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$783,595	TotalAmt
Program Services	$402,287	ProgramServicesAmt
Management And General	$206,904	ManagementAndGeneralAmt
Fundraising	$174,404	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$2,420,853	TotalAmt
Program Services	$1,196,985	ProgramServicesAmt
Management And General	$686,865	ManagementAndGeneralAmt
Fundraising	$537,003	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$2,074,425	TotalAmt
Program Services	$1,082,439	ProgramServicesAmt
Management And General	$487,763	ManagementAndGeneralAmt
Fundraising	$504,223	FundraisingAmt

Fees For Services Management FeesForServicesManagementGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$242,415	TotalAmt
Program Services	$97,066	ProgramServicesAmt
Management And General	$48,283	ManagementAndGeneralAmt
Fundraising	$97,066	FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$508,141	TotalAmt
Program Services	$57,633	ProgramServicesAmt
Management And General	$392,894	ManagementAndGeneralAmt
Fundraising	$57,614	FundraisingAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

Field	Value	IRS element (for citing)
Total	$204,997	TotalAmt
Program Services	$204,997	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	$1,181,706	TotalAmt
Fundraising	$1,181,706	FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$179,154	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$179,154	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$5,010,574	TotalAmt
Program Services	$2,770,603	ProgramServicesAmt
Management And General	$336,748	ManagementAndGeneralAmt
Fundraising	$1,903,223	FundraisingAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$16,533,412	TotalAmt
Program Services	$8,238,874	ProgramServicesAmt
Management And General	$130,075	ManagementAndGeneralAmt
Fundraising	$8,164,463	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$1,863,957	TotalAmt
Program Services	$745,583	ProgramServicesAmt
Management And General	$559,187	ManagementAndGeneralAmt
Fundraising	$559,187	FundraisingAmt

Royalties RoyaltiesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$198,411	TotalAmt
Program Services	$125,740	ProgramServicesAmt
Management And General	$38,890	ManagementAndGeneralAmt
Fundraising	$33,781	FundraisingAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$276,760	TotalAmt
Program Services	$144,731	ProgramServicesAmt
Management And General	$44,116	ManagementAndGeneralAmt
Fundraising	$87,913	FundraisingAmt

Pymt Travel Entrtnmnt Pub Ofcl PymtTravelEntrtnmntPubOfclGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$211,178	TotalAmt
Program Services	$77,693	ProgramServicesAmt
Management And General	$50,538	ManagementAndGeneralAmt
Fundraising	$82,947	FundraisingAmt

Interest InterestGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Payments To Affiliates PaymentsToAffiliatesGrp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt
Program Services	$0	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$900,298	TotalAmt
Program Services	$665,856	ProgramServicesAmt
Management And General	$126,593	ManagementAndGeneralAmt
Fundraising	$107,849	FundraisingAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$543,188	TotalAmt
Program Services	$543,188	ProgramServicesAmt
Management And General	$0	ManagementAndGeneralAmt
Fundraising	$0	FundraisingAmt

Other Expenses OtherExpensesGrp (4 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
CONSULT & PROF. FEES	$6,641,802	$5,326,482	$556,519	$758,801
EQUIP RENTAL & MAINT	$1,744,826	$1,102,803	$346,119	$295,904
EVENT PRODUCTION	$108,740	$40,854	$23,002	$44,884
MERCHANT SERVICES & BANK FEES	$1,367,858	$777,580	$94,358	$495,920

All Other Expenses AllOtherExpensesGrp

Field	Value	IRS element (for citing)
Total	$1,073,802	TotalAmt
Program Services	$534,981	ProgramServicesAmt
Management And General	$262,329	ManagementAndGeneralAmt
Fundraising	$276,492	FundraisingAmt

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$100,632,384	TotalAmt
Program Services	$65,857,438	ProgramServicesAmt
Management And General	$11,993,104	ManagementAndGeneralAmt
Fundraising	$22,781,842	FundraisingAmt

Field	Value	IRS element (for citing)
Joint Costs	Yes (X)	JointCostsInd

Total Joint Costs TotalJointCostsGrp

Field	Value	IRS element (for citing)
Total	$42,779,147	TotalAmt
Program Services	$21,416,390	ProgramServicesAmt
Management And General	$1,814,928	ManagementAndGeneralAmt
Fundraising	$19,547,829	FundraisingAmt

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$27,119,307	BOYAmt
EOY	$23,067,395	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$20,276,918	BOYAmt
EOY	$15,045,253	EOYAmt

Accounts Receivable AccountsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Receivables From Officers Etc ReceivablesFromOfficersEtcGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Rcvbl From Disqualified Prsn RcvblFromDisqualifiedPrsnGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

Field	Value	IRS element (for citing)
BOY	$6,957	BOYAmt
EOY	$9,577	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$2,239,524	BOYAmt
EOY	$2,120,424	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$12,062,424	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$8,416,953	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$2,249,769	BOYAmt
EOY	$3,645,471	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$102,135,416	BOYAmt
EOY	$119,988,473	EOYAmt

Investments Other Securities InvestmentsOtherSecuritiesGrp

Field	Value	IRS element (for citing)
BOY	$39,150,000	BOYAmt
EOY	$43,470,000	EOYAmt

Investments Program Related InvestmentsProgramRelatedGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt

Intangible Assets IntangibleAssetsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$11,357	BOYAmt
EOY	$7,468	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$193,189,248	BOYAmt
EOY	$207,354,061	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$9,143,376	BOYAmt
EOY	$9,791,057	EOYAmt

Grants Payable GrantsPayableGrp

Field	Value	IRS element (for citing)
BOY	$41,640,671	BOYAmt
EOY	$49,697,151	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$614,778	BOYAmt
EOY	$229,708	EOYAmt

Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Escrow Account Liability EscrowAccountLiabilityGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Loans From Officers Directors LoansFromOfficersDirectorsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp

Field	Value	IRS element (for citing)
BOY	$4,527,545	BOYAmt
EOY	$0	EOYAmt

Unsecured Notes Loans Payable UnsecuredNotesLoansPayableGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$55,926,370	BOYAmt
EOY	$59,717,916	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows FASB117	Yes (X)	OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$90,698,864	BOYAmt
EOY	$98,403,421	EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$46,564,014	BOYAmt
EOY	$49,232,724	EOYAmt

Cap Stk Tr Prin Current Funds CapStkTrPrinCurrentFundsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Pd In Cap Srpls Land Bldg Eqp Fund PdInCapSrplsLandBldgEqpFundGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Rtn Earn Endowment Incm Oth Fnds RtnEarnEndowmentIncmOthFndsGrp

Field	Value	IRS element (for citing)
BOY	$0	BOYAmt
EOY	$0	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$137,262,878	BOYAmt
EOY	$147,636,145	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$193,189,248	BOYAmt
EOY	$207,354,061	EOYAmt

Field	Value	IRS element (for citing)
Info In Schedule O Part XI	Yes (X)	InfoInScheduleOPartXIInd
Reconcilation Revenue Expnss	$10,629,072	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	-$693,580	NetUnrlzdGainsLossesInvstAmt
Donated Services And Use Fclts	-$179,874	DonatedServicesAndUseFcltsAmt
Investment Expense	$0	InvestmentExpenseAmt
Other Changes In Net Assets	$617,649	OtherChangesInNetAssetsAmt
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	false	AccountantCompileOrReviewInd
FS Audited	Yes (true)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Consolidated Basis Fincl Stmt	Yes (X)	ConsolidatedBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (true)	AuditCommitteeInd
Federal Grant Audit Required	false	FederalGrantAuditRequiredInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$51,441,732	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$63,291,987	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$59,972,314	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$50,983,746	CurrentTaxYearMinus1YearAmt
Current Tax Year	$99,456,148	CurrentTaxYearAmt
Total	$325,145,927	TotalAmt

Tax Rev Levied Orgnztnl Bnft170 TaxRevLeviedOrgnztnlBnft170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Govt Furn Srvc Fclts Vl170 GovtFurnSrvcFcltsVl170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$51,441,732	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$63,291,987	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$59,972,314	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$50,983,746	CurrentTaxYearMinus1YearAmt
Current Tax Year	$99,456,148	CurrentTaxYearAmt
Total	$325,145,927	TotalAmt

Field	Value	IRS element (for citing)
Substantial Contributors Tot	$20,149,718	SubstantialContributorsTotAmt
Public Support Total170	$304,996,209	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$5,667,273	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$5,221,701	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$4,928,838	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$1,217,543	CurrentTaxYearMinus1YearAmt
Current Tax Year	$1,156,360	CurrentTaxYearAmt
Total	$18,191,715	TotalAmt

Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp

Field	Value	IRS element (for citing)
Total	$0	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$124,523	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$34,200	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$86,442	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$15,070	CurrentTaxYearMinus1YearAmt
Current Tax Year	$3,574	CurrentTaxYearAmt
Total	$263,809	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$343,601,451	TotalSupportAmt
Gross Receipts Rltd Activities	$81,700,047	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.8876	PublicSupportCY170Pct
Public Support PY170	0.8199	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

Field	Value	IRS element (for citing)
Form And Line Reference	Schedule A, Part II, Line 10 Other Income	FormAndLineReferenceDesc
Explanation	DESCRIPTION - OTHER INCOME, COLUMN A - 124523.0, COLUMN B - 34200.0, COLUMN C - 86442.0, COLUMN D - 15070.0, COLUMN E - 3574.0, COLUMN F - 263809.0;	ExplanationTxt

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Total Grassroots Lobbying TotalGrassrootsLobbyingGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$26,906	FilingOrganizationsTotalAmt
Affiliated Group Total	$26,906	AffiliatedGroupTotalAmt

Total Direct Lobbying TotalDirectLobbyingGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$178,091	FilingOrganizationsTotalAmt
Affiliated Group Total	$178,447	AffiliatedGroupTotalAmt

Total Lobbying Expend TotalLobbyingExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$204,997	FilingOrganizationsTotalAmt
Affiliated Group Total	$205,353	AffiliatedGroupTotalAmt

Other Exempt Purpose Expend OtherExemptPurposeExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$88,434,283	FilingOrganizationsTotalAmt
Affiliated Group Total	$98,589,124	AffiliatedGroupTotalAmt

Total Exempt Purpose Expend TotalExemptPurposeExpendGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$88,639,280	FilingOrganizationsTotalAmt
Affiliated Group Total	$98,794,477	AffiliatedGroupTotalAmt

Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$1,000,000	FilingOrganizationsTotalAmt
Affiliated Group Total	$1,000,000	AffiliatedGroupTotalAmt

Grassroots Nontaxable GrassrootsNontaxableGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$250,000	FilingOrganizationsTotalAmt
Affiliated Group Total	$250,000	AffiliatedGroupTotalAmt

Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$0	FilingOrganizationsTotalAmt
Affiliated Group Total	$0	AffiliatedGroupTotalAmt

Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp

Field	Value	IRS element (for citing)
Filing Organizations Total	$0	FilingOrganizationsTotalAmt
Affiliated Group Total	$0	AffiliatedGroupTotalAmt

Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$1,000,000	CurrentYearMinus3Amt
Current Year Minus2	$1,000,000	CurrentYearMinus2Amt
Current Year Minus1	$1,000,000	CurrentYearMinus1Amt
Current Year	$1,000,000	CurrentYearAmt
Total	$4,000,000	TotalAmt

Field	Value	IRS element (for citing)
Lobbying Ceiling	$6,000,000	LobbyingCeilingAmt

Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$279,269	CurrentYearMinus3Amt
Current Year Minus2	$343,462	CurrentYearMinus2Amt
Current Year Minus1	$172,474	CurrentYearMinus1Amt
Current Year	$204,997	CurrentYearAmt
Total	$1,000,202	TotalAmt

Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$250,000	CurrentYearMinus3Amt
Current Year Minus2	$250,000	CurrentYearMinus2Amt
Current Year Minus1	$250,000	CurrentYearMinus1Amt
Current Year	$250,000	CurrentYearAmt
Total	$1,000,000	TotalAmt

Field	Value	IRS element (for citing)
Grassroots Ceiling	$1,500,000	GrassrootsCeilingAmt

Avg Grassroots Lobbying Expend AvgGrassrootsLobbyingExpendGrp

Field	Value	IRS element (for citing)
Current Year Minus3	$64,115	CurrentYearMinus3Amt
Current Year Minus2	$86,368	CurrentYearMinus2Amt
Current Year Minus1	$386,160	CurrentYearMinus1Amt
Current Year	$26,906	CurrentYearAmt
Total	$563,549	TotalAmt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	Schedule C, Part II-A Lobbying Expenses	FormAndLineReferenceDesc
Explanation	Public policy and advocacy initiatives have the potential to impact all people touched by breast cancer. Recognizing the importance of this work to accomplish its mission, Komen supports advocacy and lobbying efforts to achieve legislative and regulatory solutions designed to support key patient protections, expand access to high-quality care and fund critical breast health programs and cancer research.	ExplanationTxt

Schedule D IRS990ScheduleD

CY Endwmt Fund CYEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$1,342,173	BeginningYearBalanceAmt
Contributions	$0	ContributionsAmt
Investment Earnings Or Losses	$10,613	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	$0	GrantsOrScholarshipsAmt
Other Expenditures	$5,918	OtherExpendituresAmt
Administrative Expenses	$0	AdministrativeExpensesAmt
End Year Balance	$1,346,868	EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$1,337,562	BeginningYearBalanceAmt
Contributions	$0	ContributionsAmt
Investment Earnings Or Losses	$10,279	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	$0	GrantsOrScholarshipsAmt
Other Expenditures	$5,668	OtherExpendituresAmt
Administrative Expenses	$0	AdministrativeExpensesAmt
End Year Balance	$1,342,173	EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$1,333,603	BeginningYearBalanceAmt
Contributions	$0	ContributionsAmt
Investment Earnings Or Losses	$9,803	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	$0	GrantsOrScholarshipsAmt
Other Expenditures	$5,844	OtherExpendituresAmt
Administrative Expenses	$0	AdministrativeExpensesAmt
End Year Balance	$1,337,562	EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$1,362,090	BeginningYearBalanceAmt
Contributions	$0	ContributionsAmt
Investment Earnings Or Losses	-$4,016	InvestmentEarningsOrLossesAmt
Grants Or Scholarships	$0	GrantsOrScholarshipsAmt
Other Expenditures	$24,267	OtherExpendituresAmt
Administrative Expenses	$204	AdministrativeExpensesAmt
End Year Balance	$1,333,603	EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$1,377,855	BeginningYearBalanceAmt
Investment Earnings Or Losses	$10,034	InvestmentEarningsOrLossesAmt
Other Expenditures	$25,799	OtherExpendituresAmt
Administrative Expenses	$0	AdministrativeExpensesAmt
End Year Balance	$1,362,090	EndYearBalanceAmt

Field	Value	IRS element (for citing)
Board Designated Balance EOY	0.74	BoardDesignatedBalanceEOYPct
Prmnnt Endowment Balance EOY	0.24	PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY	0.02	TermEndowmentBalanceEOYPct
Endowments Held Unrelated Org	false	EndowmentsHeldUnrelatedOrgInd
Endowments Held Related Org	false	EndowmentsHeldRelatedOrgInd

Leasehold Improvements LeaseholdImprovementsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$83,890	OtherCostOrOtherBasisAmt
Depreciation	$66,413	DepreciationAmt
Book Value	$17,477	BookValueAmt

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$2,171,260	OtherCostOrOtherBasisAmt
Depreciation	$1,724,500	DepreciationAmt
Book Value	$446,760	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$9,807,274	OtherCostOrOtherBasisAmt
Depreciation	$6,626,040	DepreciationAmt
Book Value	$3,181,234	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$3,645,471	TotalBookValueLandBuildingsAmt

Other Securities OtherSecuritiesGrp

Field	Value	IRS element (for citing)
Desc	PRIVATE EQUITY FUND	Desc
Book Value	$43,470,000	BookValueAmt
Method Valuation	F	MethodValuationCd

Field	Value	IRS element (for citing)
Total Book Value Securities	$43,470,000	TotalBookValueSecuritiesAmt
Total Liability	$0	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
Schedule D, Part V, Line 4 Intended uses of endowment funds	KOMEN HAS THREE PERMANENT ENDOWMENTS: GOODMAN-BRINKER, FIRNBERG, AND A GENERAL ENDOWMENT. THE GOODMAN-BRINKER ENDOWMENT IS FOR BREAST CANCER RESEARCH FELLOWSHIPS, THE FIRNBERG ENDOWMENT IS FOR BREAST CANCER EDUCATIONAL PROGRAMS AND RESEARCH AWARDS, AND THE GENERAL ENDOWMENT'S EARNINGS ARE RESTRICTED FOR ORGANIZATIONAL MISSION ACTIVITIES.
Schedule D, Part X, Line 2 FIN 48 (ASC 740) footnote	THE ORGANIZATION IS SUBJECT TO A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. THERE WERE NO UNCERTAIN TAX POSITIONS RECORDED IN THE CONSOLIDATED FINANCIAL STATEMENTS AT MARCH 31, 2022

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (13 entries)

RegionRegionTxt	EmployeeEmployeeCnt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt
East Asia and the Pacific	1	Grantmaking	Patient Care	$500
East Asia and the Pacific	2	Grantmaking	Research	$182,226
Europe (Including Iceland and Greenland)	1	Fundraising	Fundraising Support	$13,402
Europe (Including Iceland and Greenland)	4	Grantmaking	Research	$221,030
Europe (Including Iceland and Greenland)	1	Program Services	Learning Mgmt System	$16,189
Europe (Including Iceland and Greenland)	1	Program Services	Legal Services	$7,113
Europe (Including Iceland and Greenland)	1	Program Services	Professional Membership	$3,288
North America (Canada & Mexico only)	3	Grantmaking	Research	$149,156
North America (Canada & Mexico only)	1	Program Services	Advocacy	$47,096
North America (Canada & Mexico only)	1	Program Services	Mission Tool Development	$500,639
North America (Canada & Mexico only)	1	Program Services	Professional Membership	$2,000
North America (Canada & Mexico only)	1	Program Services	Software Licenses	$22,482
Middle East and North Africa	1	Grantmaking	Treatment	$19,998

Field	Value	IRS element (for citing)
Subtotal Offices	0	SubtotalOfficesCnt
Subtotal Employees	19	SubtotalEmployeesCnt
Continuation Total Office	0	ContinuationTotalOfficeCnt
Continuation Total Employee	0	ContinuationTotalEmployeeCnt
Total Office	0	TotalOfficeCnt
Total Employee	19	TotalEmployeeCnt
Subtotal Spent	$1,185,119	SubtotalSpentAmt
Continuation Spent	$0	ContinuationSpentAmt
Total Spent	$1,185,119	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (9 entries)

RegionRegionTxt	Purpose Of GrantPurposeOfGrantTxt	Cash GrantCashGrantAmt	Manner Of Cash DisbursementMannerOfCashDisbursementTxt
East Asia and the Pacific	Research	$135,000	Electronic Fund or Wire Transfer
East Asia and the Pacific	Research	$47,226	Electronic Fund or Wire Transfer
North America (Canada & Mexico only)	Research	$58,749	Electronic Fund or Wire Transfer
North America (Canada & Mexico only)	Research	$74,992	Electronic Fund or Wire Transfer
North America (Canada & Mexico only)	Research	$15,415	Electronic Fund or Wire Transfer
Europe (Including Iceland and Greenland)	Research	$51,878	Electronic Fund or Wire Transfer
Europe (Including Iceland and Greenland)	Research	$74,685	Electronic Fund or Wire Transfer
Europe (Including Iceland and Greenland)	Research	$89,467	Electronic Fund or Wire Transfer
Sub-Saharan Africa	Treatment	$19,998	Electronic Fund or Wire Transfer

Field	Value	IRS element (for citing)
Total501c3 Org	9	Total501c3OrgCnt
Total Other Org	0	TotalOtherOrgCnt
Transfer To Foreign Corp	Yes (true)	TransferToForeignCorpInd
Interest In Foreign Trust	false	InterestInForeignTrustInd
Foreign Corp Ownership	Yes (true)	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	false	PassiveForeignInvestmestCoInd
Foreign Partnership	false	ForeignPartnershipInd
Boycott Countries	false	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
Schedule F, Part I, Line 2 Procedures for monitoring use of grant funds	AS OUTLINED IN KOMEN'S POLICIES AND PROCEDURES FOR RESEARCH AND TRAINING GRANTS, ALL GRANTEES ARE REQUIRED TO SUBMIT SCIENTIFIC PROGRESS REPORTS AND FINANCIAL REPORTS IN THE FORMAT REQUIRED BY KOMEN AND IN ACCORDANCE WITH THE SCHEDULE SET FORTH IN THE POLICIES AND ANY CHANGE REQUESTS THEY MAY HAVE FOR THEIR PROJECTS. ALL PROGRESS REPORTS AND REQUESTS ARE REVIEWED BY QUALIFIED STAFF. SEE SCHEDULE I, PART IV AND SCHEDULE O, PART IX, LINE 1 NARRATIVE FOR ADDITIONAL DETAILS.
Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements	EAST ASIA AND THE PACIFIC-Accrual,; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual,; MIDDLE EAST AND NORTH AFRICA-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual
Schedule F, Part II, Line 1 Method used to account for expenditures on org's financial statements	EAST ASIA AND THE PACIFIC-Accrual,; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual; SUB-SAHARAN AFRICA-Accrual

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
Mail Solicitations	Yes (X)	MailSolicitationsInd
Email Solicitations	Yes (X)	EmailSolicitationsInd
Phone Solicitations	Yes (X)	PhoneSolicitationsInd
In Person Solicitations	Yes (X)	InPersonSolicitationsInd
Solicitation Of Non Govt Grants	Yes (X)	SolicitationOfNonGovtGrantsInd
Special Fundraising Events	Yes (X)	SpecialFundraisingEventsInd
Agrmt Prof Fundraising Acty	Yes (true)	AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp (4 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	ActivityActivityTxt	Fundraiser Control Of FundsFundraiserControlOfFundsInd	Gross ReceiptsGrossReceiptsAmt	Retained By ContractorRetainedByContractorAmt	Net To OrganizationNetToOrganizationAmt
Event 360
55 E Jackson Blvd Suite 1010	Chicago	IL	60604	Fundraising Consultant	false	$7,185,057	$576,810	$6,608,247
Revunami Inc
228 E 85th St Suite 9C	New York	NY	10028	Marketing Consultant	false		$20,593	-$20,593
RKD Group LLC
3400 Waterview Parkway Suite 250	Richardson	TX	75080	Fundraising Consultant	false	$27,711,220	$578,703	$27,132,517
Armstrong McGuire LLC
PO Box 6485	Raleigh	NC	27628	Fundraising Consultant	false		$5,600	-$5,600

Field	Value	IRS element (for citing)
Total Gross Receipts	$34,896,277	TotalGrossReceiptsAmt
Total Retained By Contractors	$1,181,706	TotalRetainedByContractorsAmt
Total Net To Organization	$33,714,571	TotalNetToOrganizationAmt
Licensed States	CA	LicensedStatesCd
Licensed States	CO	LicensedStatesCd
Licensed States	CT	LicensedStatesCd
Licensed States	DC	LicensedStatesCd
Licensed States	FL	LicensedStatesCd
Licensed States	GA	LicensedStatesCd
Licensed States	AL	LicensedStatesCd
Licensed States	HI	LicensedStatesCd
Licensed States	ID	LicensedStatesCd
Licensed States	IL	LicensedStatesCd
Licensed States	IN	LicensedStatesCd
Licensed States	IA	LicensedStatesCd
Licensed States	KS	LicensedStatesCd
Licensed States	KY	LicensedStatesCd
Licensed States	LA	LicensedStatesCd
Licensed States	ME	LicensedStatesCd
Licensed States	AK	LicensedStatesCd
Licensed States	MD	LicensedStatesCd
Licensed States	MA	LicensedStatesCd
Licensed States	MI	LicensedStatesCd
Licensed States	MN	LicensedStatesCd
Licensed States	MS	LicensedStatesCd
Licensed States	MO	LicensedStatesCd
Licensed States	MT	LicensedStatesCd
Licensed States	NE	LicensedStatesCd
Licensed States	NV	LicensedStatesCd
Licensed States	NH	LicensedStatesCd
Licensed States	NJ	LicensedStatesCd
Licensed States	NM	LicensedStatesCd
Licensed States	NY	LicensedStatesCd
Licensed States	NC	LicensedStatesCd
Licensed States	ND	LicensedStatesCd
Licensed States	OH	LicensedStatesCd
Licensed States	OK	LicensedStatesCd
Licensed States	OR	LicensedStatesCd
Licensed States	PA	LicensedStatesCd
Licensed States	AZ	LicensedStatesCd
Licensed States	RI	LicensedStatesCd
Licensed States	SC	LicensedStatesCd
Licensed States	SD	LicensedStatesCd
Licensed States	TN	LicensedStatesCd
Licensed States	TX	LicensedStatesCd
Licensed States	UT	LicensedStatesCd
Licensed States	VT	LicensedStatesCd
Licensed States	VA	LicensedStatesCd
Licensed States	AR	LicensedStatesCd
Licensed States	WA	LicensedStatesCd
Licensed States	WV	LicensedStatesCd
Licensed States	WI	LicensedStatesCd
Licensed States	WY	LicensedStatesCd

Fundraising Event Information FundraisingEventInformationGrp

Field	Value	IRS element (for citing)
Event1	Race-Walk Events	Event1Nm
Gross Receipts Event1	$14,499,847	GrossReceiptsEvent1Amt
Charitable Contri Event1	$14,043,859	CharitableContriEvent1Amt
Gross Revenue Event1	$455,988	GrossRevenueEvent1Amt
Cash Prizes Event1	$0	CashPrizesEvent1Amt
Non Cash Prizes Event1	$304,015	NonCashPrizesEvent1Amt
Rent Facility Costs Event1	$79,551	RentFacilityCostsEvent1Amt
Food And Beverage Event1	$117,659	FoodAndBeverageEvent1Amt
Entertainment Event1	$11,009	EntertainmentEvent1Amt
Other Direct Expenses Event1	$1,431,367	OtherDirectExpensesEvent1Amt
Event2	3 Day Event	Event2Nm
Gross Receipts Event2	$9,614,231	GrossReceiptsEvent2Amt
Charitable Contri Event2	$9,343,514	CharitableContriEvent2Amt
Gross Revenue Event2	$270,717	GrossRevenueEvent2Amt
Cash Prizes Event2	$0	CashPrizesEvent2Amt
Non Cash Prizes Event2	$10,334	NonCashPrizesEvent2Amt
Rent Facility Costs Event2	$268,834	RentFacilityCostsEvent2Amt
Food And Beverage Event2	$293,462	FoodAndBeverageEvent2Amt
Entertainment Event2	$0	EntertainmentEvent2Amt
Other Direct Expenses Event2	$1,122,211	OtherDirectExpensesEvent2Amt
Other Events Total	32	OtherEventsTotalCnt
Gross Receipts Other Events	$1,904,776	GrossReceiptsOtherEventsAmt
Charitable Contri Other Events	$1,653,863	CharitableContriOtherEventsAmt
Gross Revenue Other Events	$250,913	GrossRevenueOtherEventsAmt
Cash Prizes Other Events	$0	CashPrizesOtherEventsAmt
Non Cash Prizes Other Events	$31,084	NonCashPrizesOtherEventsAmt
Rent Fclty Costs Other Events	$130,022	RentFcltyCostsOtherEventsAmt
Food And Beverage Other Events	$69,402	FoodAndBeverageOtherEventsAmt
Entertainment Other Events	$20,165	EntertainmentOtherEventsAmt
Oth Direct Expnss Other Events	$261,842	OthDirectExpnssOtherEventsAmt
Gross Receipts Total	$26,018,854	GrossReceiptsTotalAmt
Charitable Contributions Tot	$25,041,236	CharitableContributionsTotAmt
Gross Revenue Total Events	$977,618	GrossRevenueTotalEventsAmt
Cash Prizes Total Events	$0	CashPrizesTotalEventsAmt
Non Cash Prizes Total Events	$345,433	NonCashPrizesTotalEventsAmt
Rent Fclty Costs Total Events	$478,407	RentFcltyCostsTotalEventsAmt
Food And Beverage Total Events	$480,523	FoodAndBeverageTotalEventsAmt
Entertainment Total Events	$31,174	EntertainmentTotalEventsAmt
Oth Direct Expnss Total Events	$2,815,420	OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events	$4,150,957	DirectExpenseSummaryEventsAmt
Net Income Summary	-$3,173,339	NetIncomeSummaryAmt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	Schedule G, Part II Net Income Summary	FormAndLineReferenceDesc
Explanation	Gross receipts are reduced by the amount of fundraising contributions, per IRS instructions. The contributions for fiscal year 2022 were $25,041,236	ExplanationTxt

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (true)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (68 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Purpose Of GrantPurposeOfGrantTxt	Address Line2USAddress/AddressLine2Txt
Baylor College of Medicine
One Baylor Plaza BCM 206	Houston	TX	77030	741613878	501c(3)	$175,000	Research
Beth Israel Deaconess Medical Center
330 Brookline Avenue	Boston	MA	02215	042103881	501c(3)	$149,729	Research
University of OKlahoma
PO Box 36901	Oklahoma City	OK	731260901	731563627	501c(3)	$9,539	Education
Boston University
225 Bay State Rpad	Boston	MA	02215	042103547	501c(3)	$100,000	Research
Brigham and Women's Hospital
181 Longwood Ave 5th Fl	Boston	MA	02115	042312909	501c(3)	$61,803	Research
Cancer Care
275 Seventh Avenue	New York	NY	10001	131825919	501c(3)	$29,274	Education
Columbia University Med Ctr
722 West 168th St 4th Fl	New York	NY	10032	135598093	501c(3)	$260,000	Research
Dana-Farber Cancer Institute Inc
450 Brookline Ave BP 412	Boston	MA	02215	042263040	501c(3)	$1,385,042	Research
Duke University Medical Center
PO Box 602651	Charlotte	NC	282602651	560532129	501c(3)	$140,000	Research
Emory University
1599 Clifton Rd NE 4th Fl	Atlanta	GA	30322	580566256	501c(3)	$148,222	Research
Federacio De Clubes Michoacanos
1638 S Blue Island Ave	Chicago	IL	60608	412061019	501c(3)	$29,175	Screening
Fred Hutchinson Cancer Research Center
PO Box 19024	Seattle	WA	98109	563744111	501c(3)	$225,000	Research
Fulton County Health Department
700 East Oak Street	Canton	IL	61520	376000896	501c(3)	$5,438	Screening
Harvard Medical School
Holyoke Center Room 600	Cambridge	MA	02138	042103580	501c(3)	$100,000	Research	1350 Massachusetts Avenue
Indiana University (Indianapolis)
Financial Mgmt Svcs PO Box 66057	Indianapolis	IN	462666057	356001673	501c(3)	$716,595	Research
Intermountain Healthcare Foundation Inc
36 South State Street	Salt Lake City	UT	84111	942854057	501c(3)	$9,375	Research
Johns Hopkins University
1101 East 33rd Street Eastern C220	Baltimore	MD	21218	520595110	501c(3)	$834,671	Research
Lake County Health Department
3010 Grand Avenue	Waukegan	IL	60085	593502843	501c(3)	$5,105	Screening
Leland Stanford Jr University
PO Box 44253	San Francisco	CA	941444253	941156365	501c(3)	$200,000	Research
Massachusetts Institute of Technology
160 Memorial Drive	Cambridge	MA	02139	042103594	501c(3)	$200,000	Research
Mayo Clinic Jacksonville
Griffin Building Room 170	Jacksonville	FL	32224	593337028	501c(3)	$400,000	Research	4500 San Pablo Road
McDonough County Health Department
505 E Jackson Street	Macomb	IL	61455	376001537	501c(3)	$4,419	Screening
Memorial Sloan-Kettering Cancer Ctr
633 Third Avenue 28th Floor	New York	NY	10017	131924236	501c(3)	$425,000	Research
Mountain Park Health Cntr
3003 N 3rd Street Suite 1600	Phoenix	AZ	85012	860498020	501c(3)	$16,667	Education
North Carolina Central University
1801 Fayetteville Street	Durham	NC	27707	566000730	501c(3)	$50,809	Research
Northwestern University - Chicago
633 Clark Room G547	Evanston	IL	60208	362167817	501c(3)	$224,933	Research
Oregon Health & Science University
0690 SW Bancroft	Portland	OR	97239	752668014	501c(3)	$468,663	Research
Princeton University
701 Carnegie Center Suite 413	Princeton	NJ	08540	210634501	501c(3)	$100,000	Research
Providence Portland Medical Center
PO Box 13993	Portland	OR	97213	930386906	501c(3)	$165,000	Research
Roswell Park Alliance Foundation
Department of Immunology	Buffalo	NY	14263	161391608	501c(3)	$60,000	Research	Elm Carlton Streets
Rush University Medical Center
1700 W Van Buren St Suite 250	Chicago	IL	60612	362174823	501c(3)	$200,000	Research
Stanford University
PO Box 44253	San Francisco	CA	941444253	941156365	501c(3)	$100,000	Screening
Stephenson County Health Department
10 West Linden Street	Freeport	IL	61032	366006654	501c(3)	$5,125	Research
SUNY at Stony Brook
W5510 Melville Library	Stony Brook	NY	11794	141368361	501c(3)	$110,607	Education
Supporting Our Sisters International Inc
2604 Pinebrook Ave C2	Hyattsville	MD	20785	472511778	501c(3)	$2,500	Screening
Tazewell County Health Department
21306 Illinois Rt 9	Tremont	IL	615689252	376002170	501c(3)	$27,593	Screening
The Ohio State University College
700 Childrens Drive	Columbus	OH	43205	316025986	501c(3)	$142,485	Research
The University of Chicago
970 East 58th Street 3rd Fl	Chicago	IL	60637	362177139	501c(3)	$389,674	Research
The Wistar Institute
3601 Spruce Street	Philadelphia	PA	191044265	236434390	501c(3)	$165,000	Research
Tufts University
800 Washington Street	Boston	MA	02111	043400617	501c(3)	$66,840	Research
UnityPoint Health-MethodistProctor
5409 N Knoxville Ave	Peoria	IL	61614	510186460	501c(3)	$9,928	Screening
Univ of Colorado Health Sciences Cent
13001 E 17TH PLACE	Denver	CO	802910238	731563627	501c(3)	$92,496	Research
Univ of North Carolina at Chapel Hill
104 Airport Drive Suite 2200	Chapel Hill	NC	275991350	566001393	501c(3)	$775,531	Research	CB 1350
Univ of Texas MD Anderson Cancer Center
PO Box 4390	Houston	TX	772104390	746001118	501c(3)	$495,766	Research
University of Alabama at Birmingham
1530 3rd Avenue South Room 1170	Birmingham	AL	352940111	636005396	501c(3)	$90,000	Research
University of California at San Francisco
3333 California St Suite 315	San Francisco	CA	94118	946036493	501c(3)	$100,000	Research
Loyola University Chicago
820 N Michigan Ave Ste 1300	Chicago	IL	60611	361408475	501c(3)	$165,000	Research
University of Massachusetts Amherst
Goodell Bldg Room 405 Box 33210	Amherst	MA	010033210	043167352	501c(3)	$37,109	Research
University of Michigan
Alexandra Thebaud Wolverine Tower	Ann Arbor	MI	481091274	386006309	501c(3)	$423,873	Research
University of North Carolina
104 Airport Drive Suite 2200	Chapel Hill	NC	275999525	566001393	501c(3)	$100,000	Research	CB 1350
University of Notre Dame du Lac
836a Grace Hall	Notre Dame	IN	465565612	350868188	501c(3)	$60,000	Research
University of Pennsylvania
3451 Walnut Street	Philadelphia	PA	191046205	231352685	501c(3)	$211,881	Research	P-211 Franklin Bldg
University of Pittsburgh
123 University Place Suite B21	Pittsburgh	PA	152132303	250966691	501c(3)	$120,000	Research
University of Pittsburgh
3100 Cathedral Learning	Pittsburgh	PA	15260	250965591	501c(3)	$210,000	Research
University of South Carolina
1600 Hampton Street Suite 404H	Columbia	SC	29208	576001153	501c(3)	$53,727	Research
University of Utah
201 South Presidents Circle	Salt Lake City	UT	841129020	876000525	501c(3)	$220,000	Research	Room 406
University of Washington
3917 University Way NE	Seattle	WA	98105	741586031	501c(3)	$115,000	Research
UT HSC - San Antonio
7703 Floyd Curl Drive	San Antonio	TX	772293900	741586031	501c(3)	$209,959	Research
UT Southwestern Medical Center
5323 Harry Hines Blvd	Dallas	TX	753909020	746000203	501c(3)	$579,255	Research
Utah Cancer Control Program
PO Box 144620	Salt Lake City	UT	841144620	876000545	501c(3)	$30	Education
Valleywise Health Foundation
2901 E Camelback Rd Ste 202	Phoenix	AZ	85016	860777567	501c(3)	$16,667	Education
Vanderbilt University Medical Center
Dept AT 40303	Atlanta	GA	311920303	620476822	501c(3)	$627,363	Research
Virginia Commonwealth University
800 E Leigh St Suite 3100	Richmond	VA	232843039	546001758	501c(3)	$75,000	Research
VNA of Fox Valley
400 North Highland Ave	Aurora	IL	60506	362182095	501c(3)	$19,992	Screening
Wake Forest University Health Sciences
Grants Mgmt Medical Ctr Blvd	WinstonSalem	NC	27157	223849199	501c(3)	$90,000	Research
Wayne State University
5057 Woodward AVE 13th Floor	Detroit	MI	48202	366028429	501c(3)	$18,789	Research
Winnebago County Health Department
555 NCourt St PO Box 4009	Rockford	IL	611100509	364529968	501c(3)	$6,097	Screening
Yale University
2 Whitney Avenue 6th Floor	New Haven	CT	06510	030179440	501c(3)	$135,000	Research

Field	Value	IRS element (for citing)
Total501c3 Org	67	Total501c3OrgCnt
Total Other Org	0	TotalOtherOrgCnt

Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp (3 entries)

Grant TypeGrantTypeTxt	RecipientRecipientCnt	Cash GrantCashGrantAmt	Non Cash AssistanceNonCashAssistanceAmt	Valuation Method UsedValuationMethodUsedDesc
Patient Care Assistance @ $300	4894	$1,468,200	$0	fmv
Patient Care Assistance @$500	3666	$1,833,000	$0	fmv
Patient Care Assistance @ $750	705	$528,750	$0	fmv

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds.	FormAndLineReferenceDesc
Explanation	SUSAN G. KOMEN'S (KOMEN) POLICIES FOR MANAGING GRANTS FROM THE TIME OF PRE-AWARD THROUGH CLOSEOUT ARE DESIGNED TO MAXIMIZE FLEXIBILITY WHILE MAINTAINING A HIGH STANDARD OF ACCOUNTABILITY AND PRESERVING THE INTEGRITY OF THE REVIEW AND AWARD PROCESS. KOMEN REQUIRES ALL GRANTEES TO SIGN A GRANT AGREEMENT SETTING FORTH THE TERMS OF THE GRANT, INCLUDING: PURPOSE, AMOUNT, BUDGETARY RESTRICTIONS, DURATION, PAYMENT SCHEDULE, REPORTING REQUIREMENTS, AUDIT, AND EARLY TERMINATION RIGHTS. FOR RESEARCH GRANTS, SCIENTIFIC PROGRESS AND FINANCIAL OVERSIGHT IS MONITORED THROUGHOUT THE GRANT TERM BY A PH.D. OR MASTERS-LEVEL RESEARCH GRANT MANAGER. FOR COMMUNITY HEALTH AND EDUCATION GRANTS, PROGRESS AND FINANCIAL OVERSIGHT IS MONITORED OR SUPERVISED THROUGHOUT THE GRANT TERM BY QUALIFIED PROFESSIONALS SERVING AS GRANTS MANAGERS. AS OUTLINED IN KOMEN'S POLICIES AND PROCEDURES FOR RESEARCH AND TRAINING GRANTS, GRANTEES ARE REQUIRED TO SUBMIT PROGRESS AND FINANCIAL REPORTS DETAILING PROGRESS TOWARD AIMS AND OBJECTIVES, MAJOR ACCOMPLISHMENTS, KEY DELIVERABLES AND CHALLENGES ENCOUNTERED, WITH A FULL ACCOUNTING OF GRANT FUNDS EXPENDED (ACTUAL VERSUS BUDGETED EXPENSES) AND WRITTEN JUSTIFICATION OF EXPENSES. AS APPROPRIATE, THE GRANTS MANAGER MAY CONDUCT SITE VISITS WITH GRANTEES TO GAIN A BETTER UNDERSTANDING OF THEIR WORK AND ADDRESS ANY CHALLENGES IMPACTING THE FUNDED PROGRAM. ALL GRANT FUNDS MUST BE EXPENDED IN ACCORDANCE WITH THE PROJECT'S APPROVED BUDGET AND ARE DISBURSED IN ACCORDANCE WITH THE SCHEDULE DOCUMENTED WITHIN THE GRANT AGREEMENT. REQUESTS FOR CHANGES TO THE DESIGN OF THE FUNDED PROJECT OR BUDGET ARE SUBJECT TO PRIOR APPROVAL BY KOMEN IN ACCORDANCE WITH THE TERMS OF THE GRANT AGREEMENT. AS PART OF ITS OVERSIGHT PRACTICES, THE TERMS OF THE GRANT AGREEMENT MAY PROVIDE KOMEN WITH, AMONG OTHER THINGS, THE RIGHT TO REQUEST WITH REASONABLE PRIOR NOTICE TO THE GRANTEE: (1) ADDITIONAL PROGRESS AND/OR FINANCIAL REPORTING FROM THE GRANTEE, (2) GRANTEE PARTICIPATION IN SITE VISITS, TELEPHONE CONFERENCES, PRESENTATIONS, OR OTHER SPEAKING ENGAGEMENTS, AND (3) WITH PRIOR WRITTEN NOTICE, ADJUSTMENT TO THE PROJECT REPORTING PERIOD AND ASSOCIATED DISBURSEMENT OF GRANT FUNDS AT ANY TIME DURING THE GRANT TERM. SEE SCHEDULE O, PART IX, LINE 1 NARRATIVE FOR ADDITIONAL DETAILS.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Form990 Of Other Organizations	Yes (X)	Form990OfOtherOrganizationsInd
Written Employment Contract	Yes (X)	WrittenEmploymentContractInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	false	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	false	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	false	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	false	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	false	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	false	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	false	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	false	AnyNonFixedPaymentsInd
Initial Contract Exception	false	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (13 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
Dana Brown
Chief Operating Officer	$415,375	$0	$46,800	$0	$3,362	$0	$13,948	$0	$1,689	$0	$481,174	$0	$0	$0
Eunice Nakamura
General Counsel & Corporate Secretary	$241,539	$0	$26,400	$0	$1,534	$0	$8,188	$0	$6,148	$0	$283,809	$0	$0	$0
Paula Schneider
President and CEO	$609,111	$0	$68,805	$0	$4,604	$0	$15,875	$0	$15,537	$0	$713,932	$0	$0	$0
Ria Williams
Chief Financial Officer	$259,268	$0	$29,046	$0	$1,869	$0	$7,341	$0	$14,441	$0	$311,965	$0	$0	$0
Lori Maris
SVP, Ops Services & Support	$217,465	$0	$24,102	$0	$1,710	$0	$4,012	$0	$8,584	$0	$255,873	$0	$0	$0
Catherine Olivieri
SVP, Human Resources	$256,095	$0	$30,000	$0	$3,362	$0	$8,941	$0	$13,639	$0	$312,037	$0	$0	$0
Victoria Wolodzko
SVP, Mission	$302,964	$0	$34,800	$0	$2,503	$0	$6,710	$0	$3,019	$0	$349,996	$0	$0	$0
Kimberly Johnson
Former Sr. Director AAHEI	$170,979	$0	$10,000	$0	$1,445	$0	$0	$0	$1,769	$0	$184,193	$0	$0	$0
Srinivasu Avadhanula
VP, BI Platfm & Eng	$216,663	$0	$23,643	$0	$1,414	$0	$5,964	$0	$1,946	$0	$249,630	$0	$0	$0
Kari Bodell
VP, Dev Progs Strat	$203,596	$0	$24,600	$0	$1,409	$0	$5,942	$0	$2,013	$0	$237,560	$0	$0	$0
Sarah Rosales
VP, Corp Partnerships	$213,743	$0	$18,450	$0	$1,285	$0	$3,525	$0	$13,273	$0	$250,276	$0	$0	$0
Kimberly Sabelko
VP, Sci Strat & Programs	$185,656	$0	$15,000	$0	$1,556	$0	$5,008	$0	$10,715	$0	$217,935	$0	$0	$0
Michelle Strong
VP, Marketing Strat	$204,015	$0	$20,000	$0	$1,592	$0	$6,888	$0	$6,207	$0	$238,702	$0	$0	$0

Schedule M IRS990ScheduleM

Clothing And Household Goods ClothingAndHouseholdGoodsGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Noncash Contributions Rpt F990	$30,975	NoncashContributionsRptF990Amt
Method Of Determining Revenues	Cost	MethodOfDeterminingRevenuesTxt

Other Non Cash Contri Table OtherNonCashContriTableGrp (6 entries)

Non Cash CheckboxNonCashCheckboxInd	DescDesc	ContributionContributionCnt	Noncash Contributions Rpt F990NoncashContributionsRptF990Amt	Method Of Determining RevenuesMethodOfDeterminingRevenuesTxt
Yes (X)	Gift bags/Gift Cards	30	$41,795	Cost
Yes (X)	Goods Inventory	34	$96,622	Cost
Yes (X)	Photography	1	$35	Cost
Yes (X)	Supplies	4	$8,900	Cost
Yes (X)	Tickets	3	$400	Cost
Yes (X)	Travel	2	$3,600	Cost

Field	Value	IRS element (for citing)
Any Property That Must Be Held	false	AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts	false	ReviewProcessUnusualNCGiftsInd
Third Parties Used	false	ThirdPartiesUsedInd

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (13 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
Form 990, Part I, Line 6 VOLUNTEERS	VOLUNTEERS SERVE IN A VARIETY OF WAYS, BUT THE GREATEST NUMBERS OF VOLUNTEERS ASSIST WITH THE MORE THAN PINK WALKS, RACE FOR THE CURE RUNS, AND THE SUSAN G. KOMEN 3 DAY SERIES.
Form 990, Part III, Line 4 Program service accomplishments	SUSAN G. KOMEN'S MISSION IS TO SAVE LIVES FROM BREAST CANCER, BY FINDING BREAKTHROUGHS TO PREVENT, DETECT, TREAT, AND CURE BREAST CANCER, AND BY MEETING MOST CRITICAL NEEDS IN COMMUNITIES TO ENSURE EVERYONE GETS THE BREAST CANCER CARE THEY NEED WHEN THEY NEED IT. KOMEN TAKES A 360 DEGREE APPROACH TO FIGHT BREAST CANCER THROUGH . RESEARCH, TO DRIVE BREAKTHROUGHS THAT WILL BRING US NEW KNOWLEDGE AND ADVANCES IN CARE FOR ALL, . COMMUNITY HEALTH, TO EMPOWER PEOPLE WITH TRUSTWORTHY INFORMATION AND SUPPORT PEOPLE IN THEIR BREAST HEALTH JOURNEY THROUGH DIRECT SERVICES, COMMUNITY PROGRAMS AND HEALTH SYSTEMS CHANGE. . AND PUBLIC POLICY, WHERE WE ADVOCATE FOR POLICIES TO CREATE SYSTEMIC AND LASTING CHANGES THAT WILL FUND AND FACILITATE RESEARCH AND ALLEVIATE THE BURDEN ON PATIENTS AND PROTECT ACCESS TO AFFORDABLE, HIGH-QUALITY HEALTH CARE FOR ALL. KOMEN IS A LEADING GLOBAL BREAST CANCER ORGANIZATION, HAVING FUNDED MORE BREAST CANCER RESEARCH THAN ANY OTHER NONPROFIT OUTSIDE OF THE U.S. GOVERNMENT WHILE PROVIDING REAL TIME HELP TO THOSE FACING THE DISEASE. SINCE ITS FOUNDING IN 1982, KOMEN HAS FUNDED nearly $1.1 BILLION IN BREAST CANCER RESEARCH IN MORE THAN 2700 GRANTS AND more than 500 CLINICAL TRIALS CONDUCTED BY THOUSANDS OF THE WORLD'S BEST AND BRIGHTEST RESEARCHERS ACROSS THE US AND AROUND THE WORLD. KOMEN HAS ALSO PROVIDED OVER $2.3 BILLION IN FUNDING FOR PATIENT NAVIGATION, SCREENING, DIAGNOSIS, TREATMENT, EDUCATION , ADVOCACY, AND PSYCHOSOCIAL SUPPORT PROGRAMS SERVING MILLIONS OF PEOPLE IN MORE THAN 60 COUNTRIES WORLDWIDE. KOMEN WAS FOUNDED BY NANCY G. BRINKER, WHO PROMISED HER SISTER, SUSAN G. KOMEN, THAT SHE WOULD END THE DISEASE THAT CLAIMED SUZY'S LIFE. WITH THIS INVESTMENT, KOMEN IS SUPPORTING LABORATORY RESEARCH, TRANSLATIONAL STUDIES, AND CLINICAL TRIALS THAT ARE PAVING THE ROAD WITH SCIENTIFIC DISCOVERIES THAT ARE: - UNRAVELLING THE BIOLOGY OF BREAST CANCER, - LEADING TO THE DEVELOPMENT OF NEW BREAST CANCER DRUGS, - DEVELOPMENT OF NEW TECHNOLOGIES AND TESTS, AND - NEW INTERVENTIONS THAT ARE CHANGING THE STANDARD OF BREAST CANCER CARE AND IMPROVING THE DELIVERY OF THAT CARE. OUR GOAL IS TO ADVANCE PERSONALIZED MEDICINE AND IMPROVE HEALTH OUTCOMES FOR EVERYONE. KOMEN HAS HAD MORE THAN 680 RESEARCH DISCOVERIES SINCE WE STARTED TRACKING THEM IN 2016 THAT ARE MOVING US CLOSER TO THAT GOAL. NEARLY TWO-THIRDS OF THESE DISCOVERIES FOCUS ON OUR RESEARCH PRIORITIES OF CONQUERING METASTATIC AND AGGRESSIVE BREAST CANCERS AND ELIMINATING BREAST CANCER DISPARITIES. THEY INCLUDE SUCH THINGS AS NEW BIOMARKERS, NEW DRUG TARGETS, NEW TREATMENTS, AND NEW HEALTHCARE DELIVERY TOOLS IN PAVING THIS ROAD WITH SCIENTIFIC DISCOVERIES, WE'RE ALSO PAVING IT WITH HOPE. THE HOPE THAT NEW WAYS TO DETECT, DIAGNOSE, TREAT, PREVENT AND, ULTIMATELY, CURE BREAST CANCER ARE AROUND THE CORNER. THERE WHEN PEOPLE WITH BREAST CANCER NEED THEM TO ALLOW THEM TO LIVE LONGER, WITH IMPROVED QUALITY OF LIFE. RESEARCH SINCE ITS FOUNDING IN 1982, KOMEN'S RESEARCH INVESTMENTS HAVE CONTRIBUTED TO MANY MAJOR ADVANCES IN BREAST CANCER SCIENCE. THE PROGRESS HAS BEEN SIGNIFICANT - TODAY, WE KNOW THAT BREAST CANCER IS MORE THAN A SINGLE DISEASE. WE HAVE A BETTER UNDERSTANDING OF THE GENETICS OF BREAST CANCER AND THE CRITICAL NEED TO TAILOR SCREENING, DIAGNOSIS, TREATMENT, AND PREVENTION STRATEGIES TO INDIVIDUALS THROUGH ADVANCES IN PRECISION MEDICINE. KOMEN'S RESEARCH PROGRAMS ARE FOCUSED ON BREAKTHROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER THROUGH BETTER APPROACHES FOR EARLY DETECTION AND DIAGNOSIS, UNDERSTANDING METASTASIS AND RECURRENCE, DEVELOPING NOVEL THERAPIES FOR ALL STAGES OF BREAST CANCER, AND DEVELOPING NEW APPROACHES TO ADDRESS DISPARITIES IN BREAST CANCER OUTCOMES, WITH THE GOAL OF SUPPORTING WORK THAT HAS SIGNIFICANT POTENTIAL TO LEAD TO NEW TREATMENTS, TECHNOLOGIES AND INTERVENTIONS. KOMEN'S RESEARCH PROGRAMS ARE GUIDED BY 46 OF THE WORLD'S LEADERS IN BREAST CANCER RESEARCH, ONCOLOGY AND ADVOCACY. THE SCIENTIFIC ADVISORY BOARD ASSISTS KOMEN IN SETTING ITS RESEARCH STRATEGY AND PRIORITIZING ITS RESEARCH INVESTMENT. THE KOMEN SCHOLARS LEAD AND PARTICIPATE IN KOMEN'S WORLD-CLASS SCIENTIFIC PEER REVIEW PROCESS. OUR ADVOCATES IN SCIENCE BRING THE COLLECTIVE PATIENT VOICE TO KOMEN'S RESEARCH PROGRAMS AND SCIENTIFIC ACTIVITIES, EMPHASIZING URGENCY AND PATIENT IMPACT. THIS YEAR WE ANNOUNCED THE NEW CLASS OF SIX ESTEEMED BREAST CANCER RESEARCHERS AND TWO NEW PATIENT ADVOCATES TO THE KOMEN SCHOLARS. THESE WOMEN AND MEN JOIN AN EXCLUSIVE GROUP OF BREAST CANCER RESEARCHERS, CLINICIANS AND ADVOCATES WHO HELP GUIDE THE ORGANIZATION'S WORK TO SAVE LIVES AND END BREAST CANCER. KOMEN AWARDS GRANTS TO INDIVIDUAL SCIENTISTS, RESEARCH TEAMS, AND ORGANIZATIONS AROUND THE WORLD THROUGH A FAIR, TRANSPARENT, RIGOROUS, AND COMPETITIVE REVIEW PROCESS THAT ENSURES MAXIMUM IMPACT FOR OUR RESEARCH INVESTMENT. IN FY22, KOMEN AWARDED 48 GRANTS THROUGH ITS RESEARCH PROGRAMS TO SUPPORT SCIENTIFIC RESEARCH, IN THE UNITED STATES, AND CANADA. CAREER CATALYST RESEARCH GRANTS SUPPORT EARLY CAREER INVESTIGATORS CONDUCTING OUTSTANDING RESEARCH THAT WILL USE LIQUID BIOPSY TECHNOLOGY TO IMPROVE THE TREATMENT AND EARLY DETECTION OF METASTATIC BREAST CANCER. LEADERSHIP GRANTS SUPPORT KOMEN SCHOLARS PURSUING INNOVATIVE RESEARCH PROJECTS WHICH WILL IMPROVE THE UNDERSTANDING, DETECTION, TREATMENT OR PREVENTION OF BREAST CANCER, WITH A FOCUS ON CONQUERING METASTATIC BREAST CANCER AND ELIMINATING BREAST CANCER DISPARITIES. THE 48 RESEARCH GRANTS AWARDED IN FY22 ARE: CAREER CATALYST RESEARCH GRANTS: DANIEL HOLLERN, PH.D., OF SALK INSTITUTE FOR BIOLOGICAL STUDIES WILL IDENTIFY WAYS THAT METASTATIC TUMOR CELLS AVOID OR SUPPRESS THE IMMUNE SYSTEM'S B CELLS IN TRIPLE NEGATIVE BREAST CANCER (TNBC) PATIENTS, SPECIFICALLY PATIENTS THAT ALSO HAVE LIVER TUMORS. THE GOAL IS TO IMPROVE AN EXISTING TREATMENT CALLED ANTI-PDL1 THERAPY TO HELP BOOST B CELL ACTIVITY AND REDUCE MORTALITY IN TNBC PATIENTS WITH LIVER TUMORS. HARUKA ITAKURA, M.D., PH.D., OF STANFORD UNIVERSITY SCHOOL OF MEDICINE WILL CONDUCT A STUDY THAT WILL TAKE EXISTING MRI AND CT IMAGES COLLECTED FROM HER2+ BREAST CANCER PATIENTS AND USE ADVANCED DATA SCIENCE/AI TO IDENTIFY KEY FACTORS FOR PREDICTING FUTURE BRAIN METASTASIS. THE GOAL OF THIS STUDY IS TO USE NON-INVASIVE TECHNIQUES TO IDENTIFY PATIENTS WITH HER2+ BREAST CANCER WHO ARE ALSO AT RISK FOR DEVELOPING METASTATIC BRAIN TUMORS. MARIYA ROZENBLIT, M.D., OF YALE CANCER CENTER WILL CONDUCT A CLINICAL TRIAL TO EVALUATE VARIOUS THERAPIES OFFERED TO PATIENTS WITH STAGE 4 OLIGOMETASTATIC BREAST CANCER (OMBC) AND TO CREATE AN ONLINE PLATFORM THAT REGISTERS STAGE 4 OMBC PATIENTS, STANDARDIZES THE TREATMENT APPROACH AND ENABLES FOLLOW-UP DATA COLLECTION. DR. ROZENBLIT HOPES THIS COLLECTED DATA WILL DEMONSTRATE HOW THESE TREATMENT OPTIONS MAY PROMOTE LONG-TERM SURVIVAL AND FUTURE PREVENTION OF METASTATIC BREAST CANCER FOR THESE PATIENTS. TARAH BALLINGER, M.D., OF INDIANA UNIVERSITY WILL PILOT A 16-WEEK EXERCISE INTERVENTION FOR METASTATIC BREAST CANCER (MBC) PATIENTS TO DETERMINE WHETHER THE ADDITION OF EXERCISE TO THEIR COMPREHENSIVE CARE PLAN COULD IMPROVE LONG-TERM TREATMENT OUTCOMES. MARIA SOSA, PH.D., OF ICHAN SCHOOL OF MEDICINE WILL STUDY THE EFFECTIVENESS OF A NEW PROPOSED DRUG THERAPY THAT WILL BLOCK THE ACTIVITY OF ZFP296, A PROTEIN THAT IS BELIEVED TO PROMOTE TUMOR CELL GROWTH AND METASTASIS. PEDRAM RAZAVI, M.D., PH.D., OF MEMORIAL SLOAN KETTERING CANCER CENTER WILL ANALYZE CIRCULATING TUMOR CELL DNA (CTDNA) FROM EARLY-STAGE, HIGH RISK PATIENTS TO DETECT EARLY BREAST CANCER METASTASES OR ANY REMAINING BREAST CANCER CELLS AFTER TREATMENT (MINIMAL RESIDUAL DISEASE, OR MRD). DR. RAZAVI WILL USE THIS CTDNA TO IDENTIFY PERSONALIZED TREATMENTS FOR PATIENTS AT RISK FOR DEVELOPING MRD OR TREATMENT RESISTANCE, WITH THE ULTIMATE GOAL OF DECREASING THE RISK OF METASTATIC RECURRENCE AND MORTALITY. HAI WANG, PH.D., OF ROSWELL PARK CANCER INSTITUTE WILL STUDY BREAST CANCER CELL METASTASIS TO THE BONE AND THE METABOLIC CHANGES THESE METASTATIC CELLS GO THROUGH TO GROW IN THE BONE VERSUS THE PRIMARY TUMOR LOCATION IN THE BREAST. DR. WANG WILL INVESTIGATE HOW BREAST CANCER TUMOR CELLS THAT METASTASIZE TO THE BONE SWITCH THEIR SOURCE OF METABOLIC ENERGY PRODUCTION AND AIMS TO USE THESE FINDINGS TO EXPLORE NEW TREATMENT STRATEGIES THAT COULD IMPROVE SURVIVAL RATES FOR METASTATIC BREAST CANCER PATIENTS.
Form 990, Part III, Line 4 Program service accomplishments continued	SONYA REID, M.D., M.P.H., OF VANDERBILT UNIVERSITY WILL CONDUCT A CLINICAL TRIAL FOR PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+, HER2-) METASTATIC BREAST CANCER (MBC) TO DETERMINE WHETHER A GENE PANEL TEST FOR GENETIC VARIATIONS IN HR+, HER2- MBC COULD INFORM MORE EFFECTIVE TREATMENT STRATEGIES, ESPECIALLY FOR BREAST CANCER TYPES THAT ARE MORE PREVALENT IN RACIAL/ETHNIC MINORITIES. THE GOAL OF THIS PROJECT IS TO CHARACTERIZE THE IMPACT OF GENETIC VARIATION ON MBC SURVIVAL AND DISPARATE OUTCOMES, AND TO DEVELOP MORE PERSONALIZED TREATMENTS THAT COULD IMPACT CLINICAL OUTCOMES AMONG A RACIALLY DIVERSE PATIENT POPULATION. SRINIVAS MALLADI, PH.D., OF THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER WILL STUDY AND TARGET DORMANT BREAST CANCER CELLS TO PREVENT THEM FROM RECURRING AND METASTASIZING TO THE BRAIN AND INTERACTING WITH BRAIN CELLS CALLED ASTROCYTES. BY ANALYZING HOW ASTROCYTES NOURISH NEIGHBORING BREAST CANCER CELLS IN THE BRAIN WITH FATTY ACIDS, THE GOAL IS TO EVALUATE THE IMPACT OF TARGETING THE CREATION OF THESE FATTY ACIDS TO PREVENT METASTATIC RECURRENCE. LEADERSHIP GRANTS: MELINDA TELLI, M.D., OF STANFORD UNIVERSITY WILL CONDUCT TWO CLINICAL TRIALS USING LIQUID BIOPSY TO TEST FOR CIRCULATING TUMOR DNA, AN INDICATOR OF RISK FOR RELAPSE IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER (TNBC). THE HOPE IS THAT THIS LIQUID BIOPSY TECHNIQUE CAN BE USED TO MONITOR PATIENTS WHO ARE AT HIGHER RISK FOR A TNBC RELAPSE AND ALLOW FOR BETTER, MORE PERSONALIZED TREATMENTS. LAJOS PUSZTAI, M.D., OF YALE CANCER CENTER WILL TEST AN INNOVATIVE NEW TOOL FOR MEASURING TUMOR GROWTH, A NEW BIOMARKER FOR TRIPLE NEGATIVE BREAST CANCER (TNBC) TREATMENT GUIDANCE AND A NEW ANTI-CANCER THERAPY TARGETING CANCER METABOLISM. DR. PUSZTAI HOPES TO IMPROVE TNBC OUTCOMES AND PREVENT RECURRENCE OF METASTATIC TUMORS THROUGH THIS WORK. JULIE PALMER, SC.D., M.P.H., OF BOSTON UNIVERSITY WILL CONDUCT A STUDY THAT WILL USE TUMOR SAMPLES AND PSYCHOSOCIAL STRESS DATA FROM WOMEN ENROLLED IN THE BLACK WOMEN'S HEALTH STUDY TO DEMONSTRATE HOW PSYCHOSOCIAL STRESS IMPACTS BREAST CANCER BIOLOGY AND OUTCOMES. THE GOAL OF THIS PROJECT IS TO UNDERSTAND HOW PSYCHOSOCIAL STRESS INFLUENCES BREAST CANCER AND TO IDENTIFY POTENTIAL INTERVENTIONS TO REDUCE PSYCHOSOCIAL STRESS, AND TO REDUCE DISPARITIES IN BREAST CANCER MORTALITY FOR BLACK WOMEN. KOMEN SCIENTIFIC ADVISORY BOARD MEMBER KORNELIA POLYAK, M.D., PH.D., OF DANA FARBER CANCER INSTITUTE WILL DETERMINE HOW THE SIGNALING OF THE PROTEIN TRANSFORMING GROWTH FACTOR BETA (TGF) MAY CONTRIBUTE TO EARLY BREAST CANCER DEVELOPMENT, INCLUDING A SMALL MUTATION THAT IS MORE PREVALENT IN AFRICAN AMERICAN WOMEN. THIS RESEARCH WILL HELP TO IDENTIFY AT-RISK POPULATIONS AND POTENTIAL THERAPEUTIC TARGETS, WITH THE GOAL OF BETTER UNDERSTANDING AND ENDING BREAST CANCER HEALTH DISPARITIES AMONG AFRICAN AMERICAN WOMEN. YIBIN KANG, PH.D., OF PRINCETON UNIVERSITY WILL INVESTIGATE WHETHER THE ENZYME ALDH1A2 COULD BE A THERAPEUTIC TARGET FOR PREVENTING BREAST CANCER PROGRESSION. THE GOAL OF THIS RESEARCH IS TO BETTER UNDERSTAND THE IMMUNE SYSTEM'S IMPACT ON BREAST CANCER DEVELOPMENT AND TREATMENT WHILE ALSO EXPLORING THE THERAPEUTIC POTENTIAL OF ALDH1A2 AS A NEW TARGET TO ELIMINATE BREAST TUMORS AND METASTASIS. SOHRAB SHAH, PH.D., OF MEMORIAL SLOAN-KETTERING CANCER CENTER WILL PERFORM A STUDY USING TRIPLE-NEGATIVE BREAST CANCER (TNBC) TUMOR DNA AND LIQUID BIOPSY SAMPLES TO OBSERVE HOW IMMUNE CELLS AND TUMOR DNA MUTATIONS CAN EVOLVE OVER TIME WITH TREATMENT OR DISEASE PROGRESSION. THE GOAL OF THIS PROJECT IS TO DEVELOP A PREDICTIVE MODEL THAT CAN IDENTIFY THE OPTIMAL TIMEFRAME FOR INTERVENTION AFTER NEOADJUVANT CHEMOTHERAPY FOR TNBC PATIENTS THAT ARE AT THE HIGHEST RISK OF RELAPSE. STEFFI OESTERREICH, PH.D., OF UNIVERSITY OF PITTSBURGH WILL UNCOVER THE EVOLUTION OF ESTROGEN RECEPTOR POSITIVE (ER+) PRIMARY CANCER TO METASTATIC RECURRENCE USING TISSUE SAMPLES AND LIQUID BIOPSY, AND TO CREATE GUIDELINES FOR A RAPID AUTOPSY PROGRAM TO BETTER UNDERSTAND METASTATIC DISEASE. THIS WORK WILL CREATE RICH DATASETS FOR OTHER RESEARCHERS AND UNCOVER BETTER TREATMENT OPTIONS FOR PREVENTING THE RECURRENCE OF METASTATIC TUMORS. AMELIE RAMIREZ, DR.P.H., M.P.H., OF THE UNIVERSITY OF TEXAS HEALTH SCIENCES CENTER AT SAN ANTONIO WILL STUDY THE IMPACT OF A CULTURALLY ADAPTED, HOLISTIC BREAST CANCER SURVIVORSHIP PROGRAM ON LATINA BREAST CANCER SURVIVORS THAT INCLUDES YOGA, MEDITATION AND DIETARY GUIDANCE. THE GOAL OF THIS PROJECT IS TO IDENTIFY WHETHER A HOLISTIC SURVIVORSHIP PROGRAM CAN IMPROVE THE QUALITY OF LIFE AND HEALTH OUTCOMES FOR LATINA BREAST CANCER SURVIVORS. ALANA WELM, PH.D., OF THE UNIVERSITY OF UTAH WILL RESEARCH A MOLECULE CALLED SHORT FORM OF RON (SFRON) THAT IS CURRENTLY BEING STUDIED IN CLINICAL TRIALS AS A THERAPEUTIC TARGET TO BLOCK BREAST CANCER TUMOR AND METASTASIS GROWTH. DR. WELM WILL STUDY SFRON TO DETERMINE HOW IT FUNCTIONS IN METASTASIS, AND THE ANTI-TUMOR IMMUNE RESPONSE OF THE BODY. THE GOAL OF THIS PROJECT IS TO IDENTIFY HOW SFRON AND THE IMMUNE SYSTEM MAY BE HARNESSED TO DEVELOP MORE EFFECTIVE TREATMENTS FOR PATIENTS WITH METASTATIC BREAST CANCER. LEADERSHIP GRANTS - NEW KOMEN SCHOLARS: ALLISON KURIAN, M.D., OF STANFORD UNIVERSITY WILL TEST AN ETHNICALLY DIVERSE STUDY GROUP OF PATIENTS USING A NEW LIQUID BIOPSY TECHNIQUE THAT CAN DETECT PRIMARY AND RECURRENT BREAST CANCER AT AN EARLIER STAGE USING LESS GENETIC MATERIAL. THE GOAL OF THIS PROJECT IS TO IDENTIFY WHICH PATIENT POPULATIONS COULD BENEFIT FROM EARLIER BREAST CANCER DETECTION USING THIS NEW STRATEGY. SUNIL BADVE, M.D., FRCPATH, OF EMORY UNIVERSITY WILL STUDY THE STRUCTURAL DIVERSITY OF BREAST CANCER PATIENT TUMOR CELLS AND THEIR RESISTANCE TO TREATMENTS THAT USE CDK 4/6 INHIBITORS, AND TO USE THIS DATA TO DEVELOP NEW THERAPEUTIC STRATEGIES TO PREVENT RESISTANCE AND RECURRENCE NANCY LIN, M.D., OF DANA FARBER CANCER INSTITUTE WILL EXPLORE WAYS TO IMPROVE THE EFFECTIVENESS OF ANTIBODY-DRUG CONJUGATES FOR PATIENTS WITH METASTATIC BREAST CANCER (MBC). BY USING TISSUE AND PLASMA SAMPLES FROM PATIENTS TREATED WITH THESE DRUGS, DR. LIN AIMS TO UNCOVER HOW TO PREVENT RESISTANCE TO THESE THERAPIES OVER TIME AND IMPROVE LONG-TERM TREATMENT OUTCOMES FOR MBC PATIENTS. SARA M. TOLANEY, M.D., M.P.H., OF DANA FARBER CANCER INSTITUTE WILL TEST THE ABILITY OF AN ANTIBODY-DRUG CONJUGATE DRUG CALLED SACITUZUMAB GOVITECAN (SG) TO INCREASE RESPONSIVENESS TO PEMBROLIZUMAB TREATMENT IN METASTATIC TRIPLE NEGATIVE BREAST CANCER AND HR+/HER2- METASTATIC BREAST CANCER PATIENTS. THIS RESEARCH WILL HELP DETERMINE WHETHER COMBINATION THERAPY USING BOTH SG AND PEMBROLIZUMAB COULD IMPROVE LONG-TERM SURVIVAL OUTCOMES FOR MBC PATIENTS. CYNTHIA MA, M.D., PH.D., OF WASHINGTON UNIVERSITY WILL PERFORM A STUDY USING PATIENT TUMOR SAMPLES COLLECTED POST-SURGERY AND FOLLOWING ENDOCRINE THERAPY TO IDENTIFY GENETIC CHANGES AND MECHANISMS OF ENDOCRINE RESISTANCE. DR. MA HOPES THAT THIS DATA WILL HELP TO IDENTIFY WHICH PATIENTS MAY DEVELOP RESISTANCE TO ENDOCRINE THERAPY AND GUIDE THE DEVELOPMENT OF MORE PERSONALIZED TREATMENTS THAT WILL SAVE LIVES. JORGE REIS-FILHO, M.D., PH.D., FRCPATH, OF MEMORIAL SLOAN-KETTERING CANCER CENTER WILL INVESTIGATE HOW DEFECTS TO DNA REPAIR PROCESSES CAUSE INCREASED INSTABILITY AND RESISTANCE TO ANTI-ESTROGEN THERAPY IN ESTROGEN RECEPTOR POSITIVE (ER+) BREAST CANCER CELLS. THIS RESEARCH WILL PROVIDE VALUABLE INSIGHT INTO THE EVOLUTION OF THERAPEUTIC RESISTANCE OF ER+ BREAST CANCER CELLS THAT CAN BE USED FOR FUTURE DEVELOPMENT OF MORE EFFECTIVE TREATMENTS. SCIENTIFIC ADVISORY BOARD MEMBER ADRIAN LEE, PH.D., OF THE UNIVERSITY OF PITTSBURGH WILL DEVELOP AND CHARACTERIZE A LIVING BIOBANK FROM VARIOUS NORMAL AND BREAST CANCER SPECIMENS DERIVED FROM PATIENT SAMPLES. THIS BIOBANK WILL SERVE AS A PUBLIC RESOURCE FOR RESEARCHERS WITH A FOCUS ON DIVERSITY IN RACE (ANCESTRY) AND BREAST CANCER SUBTYPES AND WILL ACCELERATE RESEARCH LEADING TO NEW INSIGHTS IN DRUG RESISTANCE AND PROGRESSION, NEW THERAPEUTIC TARGETS, AND IMPROVED CLINICAL OUTCOMES. ANGELA DEMICHELE, M.D., M.S.C.E., OF THE UNIVERSITY OF PENNSYLVANIA WILL INVESTIGATE MINIMAL RESIDUAL DISEASE AND DORMANT TUMOR CELLS BY USING NEW ASSAYS TO DETECT DISSEMINATED TUMOR CELLS AND CTDNA IN PATIENT TUMOR AND BLOOD SAMPLES. SHE WILL IDENTIFY AT-RISK PATIENTS, DIFFERENTIATE BETWEEN DORMANT AND REACTIVATED BREAST CANCER CELLS, AND MORE ACCURATELY EVALUATE THE IMPACT OF TREATMENTS ON DORMANT CELLS, WITH THE GOAL OF PREVENTING METASTATIC BREAST CANCER RECURRENCE AND DEATH AND IMPROVING THE QUALITY OF LIFE FOR SURVIVORS.
Form 990, Part III, Line 4 Program service accomplishments continued	MARIANA CHAVEZ MACGREGOR, M.D., M.SC., FASCO, OF THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER WILL STUDY THE SOCIAL AND POLICY-LEVEL FACTORS THAT AFFECT BREAST CANCER PATIENTS FROM UNDERSERVED POPULATIONS WHO FREQUENTLY ENCOUNTER MORE BARRIERS TO SUCCESSFUL TREATMENT THAN OTHER PATIENTS. THE GOAL IS TO IDENTIFY WHAT FACTORS CREATE THESE DISPARITIES AND DEVELOP STRATEGIES THAT WILL STRENGTHEN THE QUALITY OF CARE AND IMPROVE TREATMENT OUTCOMES FOR UNDERSERVED PATIENTS. MBC COLLABORATIVE RESEARCH INITIATIVE MELISSA TROESTER M.D., PH.D. AND TERRY HYSLOP PH.D. ARE COLLABORATING ON A PROPOSAL TO LEVERAGE HIGH QUALITY, INDIVIDUAL-LEVEL TUMOR BIOLOGY AND SOCIAL DETERMINANTS OF HEALTH DATA IN THE CAROLINA BREAST CANCER STUDY (CBCS) DATA TOGETHER WITH COMMUNITY-LEVEL VARIABLES TO EVALUATE HOW STRESS CONTRIBUTES TO HIGHER METASTASIS AND WORSE BREAST CANCER OUTCOMES IN BLACK WOMEN WHEN COMPARED TO WHITE WOMEN. ZACH HARTMAN PH.D. AND BENJAMIN VINCENT M.D. WILL WORK TOGETHER ON A PROPOSAL TO DETERMINE HOW TO MAKE METASTATIC TRIPLE-NEGATIVE BREAST CANCERS MORE SENSITIVE TO IMMUNOTHERAPIES. THE COLLABORATORS PROPOSE A METHOD OF STIMULATING THE ANTI-TUMOR RESPONSE WITH VACCINE TECHNOLOGIES TO INDUCE A SUSTAINABLE, ROBUST, AND BROAD STIMULUS TO THE INNATE IMMUNE SYSTEM THAT WILL BE TESTED FOR THE ABILITY TO ELIMINATE DISTANT METASTASIS. JENIFER FREEDMAN PH.D., STEVEN PATIERNO PH.D., AND KATIE HOADLEY, PH.D. ARE COLLABORATING TO INVESTIGATE DIFFERENCES IN BREAST CANCER OUTCOME BY RACE AS BLACK WOMEN SUFFER DISPROPORTIONATELY AND WITH OFTEN A WORSE PROGNOSIS. THE STUDY LEADERS IDENTIFIED BIOLOGICAL DIFFERENCES IN CANCER BETWEEN AFRICAN AND EUROPEAN ANCESTRY THAT RESULTED FROM A PROCESS CALLED SPLICING. THE RESEARCHERS IN THIS PROPOSAL SEEK TO DETERMINE IF THESE DIFFERENCES CAUSE BREAST CANCER CELLS TO GROW AND SPREAD MORE QUICKLY. OPPORTUNITY GRANTS: MONICA M. BERTAGNOLLI, M.D., OF THE ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY WILL RECEIVE $249,429 TO PERFORM A GENOMIC ANALYSIS OF PAIRED GERMLINE AND PRE-TREATMENT TUMOR SAMPLES FROM POSTMENOPAUSAL WOMEN WITH STAGE 2 AND 3 ER+/HER2-NEGATIVE (HER2-) BREAST CANCER COLLECTED THROUGH THE ALTERNATE TRIAL. THE GOAL IS TO ESTIMATE THE EFFECT OF GENE MUTATIONS ON ENDOCRINE THERAPY RESISTANCE, DEVELOP BIOMARKER TESTS TO DETECT RESIDUAL DISEASE AND ADVANCE PRECISION MEDICINE CAPABILITIES IN THE FIELD OF ER+ BREAST CANCER. ETTA D. PISANO, M.D., OF THE ECOG-ACRIN CANCER RESEARCH GROUP WILL BE AWARDED $247,248 TO IMPLEMENT WAYS TO IMPROVE AFRICAN-AMERICAN PARTICIPATION IN THE TOMOSYNTHESIS MAMMOGRAPHIC IMAGING SCREENING TRIAL (TMIST) BIOSPECIMEN SUB-STUDY THROUGH THE DEVELOPMENT AND DISSEMINATION OF EDUCATIONAL MATERIALS HIGHLIGHTING THE IMPORTANCE OF PARTICIPATION IN BIOSPECIMEN RESEARCH. THIS PROJECT WILL INCREASE THE DIVERSITY OF PATIENT SAMPLES IN THE EXISTING BIOBANK THAT WILL BE USED TO SUPPORT FUTURE STUDIES FOCUSED ON BREAST CANCER SCREENING, DIAGNOSIS, AND TREATMENT INTERVENTIONS. NADINE M. TUNG, M.D., OF THE ECOG-ACRIN CANCER RESEARCH GROUP WILL BE AWARDED $249,256 TO EXPAND RESEARCH QUESTIONS IN THE COMPASSHER2 PCR TRIAL TO DETERMINE WHETHER UNIQUE BIOMARKERS IDENTIFIED IN STAGE 2 OR 3 HER2-POSITIVE (HER2+) BREAST CANCER PATIENT TUMOR SAMPLES CAN BE USED TO PREDICT OUTCOMES OF PRE-SURGERY THERAPY. THE GOAL OF THIS PROJECT IS TO PROVIDE DATA THAT CAN BE USED TO PERSONALIZE TREATMENT DECISIONS, IMPROVE QUALITY OF LIFE, AND OPTIMIZE TREATMENTS FOR PATIENTS DIAGNOSED WITH HER2+ BREAST CANCER. ANNA MARIA V. STORNIOLO, M.D., OF INDIANA UNIVERSITY (IU) WILL RECEIVE TWO OPPORTUNITY GRANTS TOTALING $1,803,000 TO SUPPORT THE SUSAN G. KOMEN TISSUE BANK (KTB) AT THE IU SIMON CANCER CENTER, THE WORLD'S ONLY BIOREPOSITORY OF NORMAL BREAST TISSUE. THESE GRANTS SUPPORT THE COLLECTION AND STORAGE OF BIOSAMPLES, INCLUDING WHOLE BLOOD, DNA, SERUM, PLASMA, AND HEALTHY BREAST TISSUE FROM WOMEN NOT KNOWN TO HAVE BREAST CANCER, AS WELL AS THE DISTRIBUTION OF THE SAMPLES TO RESEARCHERS WORLDWIDE. ACCESS TO THESE NORMAL TISSUE SAMPLES PROVIDE RESEARCHERS THE OPPORTUNITY TO UNDERSTAND THE CHANGES THAT HAPPEN IN A NORMAL BREAST AND HOW THESE MOLECULAR MECHANISMS ARE ALTERED IN THE MALIGNANT PROCESS. EDUCATION KOMEN IS A TRUSTED SOURCE OF BREAST CANCER INFORMATION FOR PEOPLE ALL OVER THE WORLD AND IS INSTRUMENTAL IN CONNECTING PEOPLE WITH THE RESOURCES THEY NEED IN THEIR FIGHT AGAINST BREAST CANCER. OUR WEBSITE, KOMEN.ORG, PROVIDES CURRENT, SAFE, ACCURATE, COMPREHENSIVE, AND UNBIASED INFORMATION ABOUT BREAST CANCER, BASED ON SCIENTIFIC EVIDENCE. CONTENT IS OFFERED IN A VARIETY OF FORMATS INCLUDING INTERACTIVE VIDEO USING ANIMATION AND VOICEOVER IN ENGLISH AND SPANISH, ILLUSTRATIONS, CHARTS, GRAPHS, AND SHORT VIDEOS TO MEET THE LEARNING PREFERENCES AND NEEDS OF OUR WEB VISITORS. THE ABOUT BREAST CANCER AND PORTIONS OF THE PATIENT & CAREGIVER SECTIONS OF KOMEN'S WEBSITE, CO-DEVELOPED WITH HARVARD MEDICAL SCHOOL FACULTY AND DANA-FARBER CANCER INSTITUTE STAFF, RECEIVED NEARLY 3 MILLION PAGE VIEWS DURING FY22. KOMEN LAUNCHED THE CLINICAL TRIALS INITIATIVE ON KOMEN.ORG WITH THE GOAL OF EDUCATING PEOPLE ABOUT THE ROLE CLINICAL TRIALS, INCLUDING THOSE FROM UNDER- REPRESENTED POPULATIONS, AND EMPOWERING PEOPLE WITH INFORMATION ON TRIALS AND RESOURCES, INCLUDING OUR CLINIAL TRIALS HELPLINE. THE RESOURCES HELP TO ENSURE PATIENTS ARE EQUIPPED TO MAKE INFORMED DECISIONS REGARDING TRIAL PARTICIPATION IN PARTNERSHIP WITH THEIR HEALTH CARE PROVIDERS. THE INITIATIVE ALSO RAISES AWARENESS OF THE DIFFERENT TYPES OF TRIALS, INCLUDING TRIALS SUPPORTED BY KOMEN, FOCUSED ON RISK, SCREENING AND EARLY DETECTION, TREATMENT, FAMILY SUPPORT, QUALITY OF LIFE AND SURVIVORSHIP. KOMEN ALSO PROVIDES EVIDENCE-BASED, EASY-TO-READ EDUCATIONAL MATERIALS IN DOWNLOADABLE FORMATS ON KOMEN.ORG. EXAMPLES OF KOMEN EDUCATIONAL MATERIALS INCLUDE: A) BREAST SELF-AWARENESS MESSAGE CARDS IN MORE THAN 40 LANGUAGES, B) BREAST CANCER SPECIFIC BROCHURES AND FACTSHEETS, C) BOOKLETS WITH SUPPORT INFORMATION FOR SURVIVORS AND CO-SURVIVORS, AND D) TOOLKITS FOR BREAST CANCER OUTREACH AND EDUCATION FOR HISPANIC/LATINO IN ENGLISH AND SPANISH, FOR BLACK AND AFRICAN AMERICAN COMMUNITIES AND FOR LESBIANS, BISEXUAL WOMEN AND TRANSGENDER AND QUESTIONING/QUEER PEOPLE. IN ADDITION, IN FY22 KOMEN CONTINUED TO SUPPORT THE METASTATIC BREAST CANCER (MBC) COMMUNITY BY HOSTING 25 VIRTUAL EVENTS THROUGH THE MBC IMPACT SERIES. THESE EVENTS PROVIDED PEOPLE LIVING WITH METASTATIC BREAST CANCER AND THEIR LOVED ONES A SAFE, COLLABORATIVE SPACE TO GATHER INFORMATION AND DISCOVER PRACTICAL RESOURCES TO HELP MAKE DECISIONS FOR IMPROVED PHYSICAL AND EMOTIONAL HEALTH. PATIENT SUPPORT AT KOMEN, WE ARE FOCUSED ON SAVING LIVES BY REMOVING BARRIERS AND ENSURING ALL PEOPLE RECEIVE THE CARE THEY NEED THROUGH KOMEN'S PATIENT CARE CENTER. OFFICIALLY LAUNCHED IN FY22, THE KOMEN PATIENT CARE CENTER IS A SUITE OF INTEGRATED DIRECT PATIENT PROGRAMS THAT ENSURE NO ONE FACES BREAST CANCER ALONE. THE PATIENT CARE CENTER PROGRAMS AND SERVICES INCLUDE THE BREAST CARE HELPLINE, SCREENING & DIAGNOSTICS PROGRAM, FINANCIAL ASSISTANCE PROGRAM, AND PATIENT NAVIGATION, ALL OF WHICH PROVIDE SUPPORT AND RESOURCES FOR PEOPLE IN LOCAL COMMUNITIES ACROSS THE COUNTRY. KOMEN'S PROGRAMS AND SERVICES REMOVE BARRIERS TO CARE AND WORK SEAMLESSLY TOGETHER SO A PERSON CAN ACCESS ALL THE PROGRAMS THROUGH ONE CENTRAL SOURCE. THE OVERARCHING GOAL OF OUR PATIENT CARE CENTER IS TO SAVE LIVES BY ENSURING PATIENTS STAY IN THE BREAST CANCER CONTINUUM OF CARE, OVERCOME BARRIERS AND CHALLENGES TO HIGH-QUALITY BREAST CARE SERVICES, COMPLETE TREATMENT, AND HAVE A HIGH QUALITY OF LIFE AND IMPROVED LONG-TERM OUTCOMES. THE PATIENT CARE CENTER SERVED ALMOST 27,000 PEOPLE IN FY22. METASTATIC BREAST CANCER COLLABORATIVE RESEARCH INITIATIVE KOMEN LAUNCHED THE METASTATIC BREAST CANCER COLLABORATIVE RESEARCH INITIATIVE (MBCCRI) WITH A PILOT PROGRAM AT DUKE UNIVERSITY AND THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL. THE GOAL IS TO CATALYZE AND SUPPORT MULTI-INSTITUTIONAL RESEARCH COLLABORATIONS AND BRING TOGETHER THE BEST AND BRIGHTEST RESEARCHERS AT SELECT INSTITUTIONS TO SHARE IDEAS, EXPERTISE AND RESOURCES. KOMEN WILL SUPPORT RESEARCH GRANT TO FIND BREAKTHROUGH DISCOVERIES TO END METASTATIC BREAST CANCER.
Form 990, Part III, Line 4 Program service accomplishments continued	INFLAMMATORY BREAST CANCER COLLABORATIVE FOR THE FIRST TIME, KOMEN IS LEADING TO DRIVE A NEW DIAGNOSTIC DEFINITION OF BREAST CANCER, SPECIFICALLY INFLAMMATORY BREAST CANCER, A DEADLY AND AGGRESSIVE FORM OF CANCER. KOMEN HAS PARTNERED WITH THE INFLAMMATORY BREAST CANCER RESEARCH FOUNDATION AND THE MILBURN FOUNDATION TO CONVENE PATIENT ADVOCATES, BREAST CANCER RESEARCHERS AND CLINICIANS TO REVIEW THE STATE OF IBC CARE AND RESEARCH GLOBALLY AND PROPOSE SPECIFIC INITIATIVES TO MOVE THE FIELD FORWARD. THE OUTCOME OF THE DISCUSSIONS WAS ABUNDANTLY CLEAR: THE FIELD NEEDS A FORMAL DEFINITION OF IBC. WITHOUT A CLEAR DEFINITION, BOTH PATIENT CARE AND RESEARCH SUFFER. DIAGNOSIS REMAINS SUBJECTIVE AND TREATMENT VARIABLE. THE GOAL IS TO MOVE BEYOND THE SUBJECTIVE 'CLINICAL DIAGNOSIS' TO A SET OF SPECIFIC DIAGNOSTIC CRITERIA AND SCORING SYSTEM THAT WILL ADVANCE IBC RESEARCH AND FACILITATE THE DISCOVERIES THAT WILL IMPROVE CARE OF IBC PATIENTS. A PROPOSED DEFINITION OF IBC, BASED ON A REVIEW OF CLINICAL, AND PATHOLOGIC FEATURES WAS SUBMITTED FOR PUBLICATION. BIG DATA FOR BREAST CANCER KOMEN CONTINUES WORK ON THE BIG DATA FOR BREAST CANCER INITIATIVE, WHICH IS AIMED AT USING BIG DATA TO FUEL SCIENTIFIC DISCOVERIES AND ACCELERATE THE DELIVERY OF EQUITABLE, PATIENT-FOCUSED CARE. KOMEN EMPOWERS BREAST CANCER PATIENTS, ADVOCATES AND THE PUBLIC WITH INFORMATION AND TOOLS TO MAKE DATA SHARING UNDERSTANDABLE THROUGH THE BIG DATA FOR BREAST CANCER PATIENTS EDUCATIONAL PROGRAMS. WE ALSO ADDRESS THE CHALLENGES OF INCORPORATING BIG DATA APPLICATIONS INTO BREAST CANCER RESEARCH AND CLINICAL CARE THROUGH WORKING WITH PARTNERS REPRESENTING A VARIETY OF STAKEHOLDERS IN BREAST CANCER RESEARCH. ADDITIONALLY, KOMEN SUPPORTS DATA SCIENCE PROJECTS TO IMPROVE BREAST CANCER OUTCOMES AND SAVE LIVES. PUBLIC POLICY AND ADVOCACY SUSAN G. KOMEN IS THE NONPARTISAN VOICE OF MORE THAN 3.8 MILLION BREAST CANCER SURVIVORS, THOSE LIVING WITH THE DISEASE AND THE PEOPLE WHO LOVE THEM. KOMEN WORKS TO EDUCATE PEOPLE ABOUT PUBLIC POLICY ISSUES, SO THEY ARE EMPOWERED TO BECOME FORCEFUL ADVOCATES FOR THEMSELVES AND THEIR NEIGHBORS, AND THEN UNITES THEIR COLLECTIVE VOICES FOR MAXIMUM IMPACT. THROUGH OUR CENTER FOR PUBLIC POLICY, KOMEN ENSURES THAT OUR POLICYMAKERS ARE EDUCATED ABOUT THE NEEDS OF BREAST CANCER PATIENTS AND PRIORITIZE THE ISSUES IMPACTING THEM. ONLY THROUGH INFORMED GOVERNMENT ACTION CAN WE MAKE THE BROAD, SYSTEMIC AND LASTING CHANGE REQUIRED. KOMEN'S 2021-2022 PUBLIC POLICY AND ADVOCACY PRIORITIES INCLUDED: EXPANDING ACCESS TO AFFORDABLE, HIGH-QUALITY HEALTH CARE FOR ALL PATIENT POPULATIONS; SUPPORTING INCREASED STATE AND FEDERAL FUNDING FOR BREAST CANCER RESEARCH AND INCREASED EDUCATION, UTLIZATION OF AND ACCESS TO CLINICAL TRIALS; SUPPORTING STATE AND FEDERAL FUNDING FOR THE CENTERS FOR DISEASE CONTROL AND PREVENTION'S (CDC) NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM (NBCCEDP); ADVOCATING FOR STATE AND FEDERAL POLICIES TO IMPROVE INSURANCE COVERAGE OF BREAST CANCER TREATMENTS, INCLUDING THOSE THAT WOULD REQUIRE ORAL PARITY, PRECLUDE SPECIALTY TIERS AND PREVENT STEP THERAPY PROTOCOLS; AND ADVOCATING FOR STATE AND FEDERAL POLICIES TO REDUCE OR ELIMINATE OUT-OF-POCKET COSTS FOR MEDICALLY NECESSARY DIAGNOSTIC IMAGING. IN ADDITION TO THE STATE AND FEDERAL WORK ON OUR PUBLIC POLICY AND ADVOCACY PRIORITIES, KOMEN ALSO ENGAGED ON ISSUES RELATED TO CUSTOM BREAST PROTHESES, GENETIC AND GENOMIC TESTING, LYMPHEDEMA, MEDICARE WAITING PERIODS, PALLIATIVE CARE, SURPRISE MEDICAL BILLING AND SURVIVORSHIP. KOMEN DEVELOPED AND IMPLEMENTED ADVOCACY CAMPAIGNS TO ENCOURAGE LAWMAKERS AND AGENCY OFFICIALS TO SUPPORT AND IMPLEMENT PROGRAMS THAT WOULD ADVANCE OUR PRIORITY ISSUES. KOMEN CONTINUED TO RECRUIT AND ENGAGE ADVOCATES TO FURTHER STRENGTHEN ITS GRASSROOTS ADVOCACY NETWORK.
Form 990, Part VI, Line 1a Executive Committee	THE ORGANIZATION'S BYLAWS PROVIDE FOR AN EXECUTIVE COMMITTEE COMPRISED OF A MINIMUM OF FIVE MEMBERS INCLUDING THE BOARD CHAIR, THE PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND ADDITIONAL BOARD MEMBERS, AS RECOMMENDED BY THE GOVERNANCE COMMITTEE AND APPOINTED BY THE BOARD OF DIRECTORS. MEMBERS OF THE EXECUTIVE COMMITTEE MUST EITHER BE DIRECTORS OF THE ORGANIZATION OR THE PRESIDENT AND CHIEF EXECUTIVE OFFICER. THE BYLAWS PROVIDE THE EXECUTIVE COMMITTEE WITH THE AUTHORITY TO: (A) APPOINT MEMBERS TO NON-STANDING COMMITTEES OF THE ORGANIZATION, AND NAME CHAIRS OF SUCH COMMITTEES; (B) AUTHORIZE UNBUDGETED DISBURSEMENTS BY THE ORGANIZATION IN ACCORDANCE WITH THE SPECIFIC EXPENDITURE AUTHORITY PRESCRIBED BY THE BOARD OF DIRECTORS; (C) EMPLOY AGENTS; AND (D) CARRY INTO EXECUTION SUCH OTHER MEASURES AS IT DETERMINES WILL PROMOTE THE PURPOSE OF THE ORGANIZATION. THE COMMITTEE ALSO MAY EXERCISE, WHEN THE BOARD IS NOT IN SESSION, ALL OF THE AUTHORITY OF THE BOARD IN THE MANAGEMENT OF THE BUSINESS AND AFFAIRS OF THE ORGANIZATION WITH CERTAIN EXCEPTIONS SUCH AS REPEALING ANY BOARD RESOLUTIONS, AMENDING THE ORGANIZATION'S ARTICLES OR BYLAWS, OR MERGING OR DISSOLVING THE ORGANIZATION. THIS DELEGATION DOES NOT RELIEVE THE BOARD OF ANY OF ITS RESPONSIBILITIES IMPOSED BY LAW, AND THE COMMITTEE ENDEAVORS TO LIMIT ITS EXERCISE OF AUTHORITY TO TIME SENSITIVE ISSUES.
Form 990, Part VI, Line 11b Review of form 990 by governing body	MANAGEMENT PREPARES THE MATERIALS FOR THE FORM 990, WITH THE ASSISTANCE OF AND REVIEW BY EXTERNAL ACCOUNTANTS. SENIOR LEVEL MANAGEMENT REVIEW AND COMMENT ON THE FINAL DRAFT OF THE FORM 990 FOR SUBSEQUENT PRESENTATION TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWS, MAKES RECOMMENDATIONS, AND APPROVES THE FORM 990 FOR PRESENTATION TO THE BOARD OF DIRECTORS. THEREAFTER, THE BOARD OF DIRECTORS REVIEWS AND APPROVES THE FORM 990 PRIOR TO FILING.
Form 990, Part VI, Line 12c Conflict of interest policy	KOMEN'S CONFLICT OF INTEREST POLICY REQUIRES EVERY BOARD MEMBER, OFFICER, COMMITTEE MEMBER, ADVISORY BOARD MEMBER, AND EMPLOYEE TO AVOID CONFLICTS OF INTEREST. IT ALSO REQUIRES THESE PERSONS TO REPORT ANY ACTUAL AND/OR POTENTIAL CONFLICTS OF INTEREST AS SOON AS POSSIBLE. REPORTS ARE REVIEWED BY THE GENERAL COUNSEL'S OFFICE AND/OR AUDIT COMMITTEE, AND APPROPRIATE ACTION IS TAKEN PURSUANT TO THE CONFLICT OF INTEREST POLICY. FURTHER, KOMEN PRODUCES AN ANNUAL SURVEY REQUIRING ALL BOARD MEMBERS, OFFICERS, COMMITTEE MEMBERS, ADVISORY BOARD MEMBERS, AND EMPLOYEES TO REVIEW THE CONFLICT OF INTEREST POLICY AND DISCLOSE ANY ADDITIONAL ACTUAL/POTENTIAL CONFLICTS OF INTEREST. THESE ANNUAL DISCLOSURES ARE REVIEWED IN THE SAME MANNER. THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS RECEIVES, AND REVIEWS ALL REPORTED ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AND THE RELATED ACTION TO ADDRESS THEM.
Form 990, Part VI, Line 15a Process to establish compensation of top management official	THE HUMAN CAPITAL MANAGEMENT COMMITTEE OF THE BOARD OF DIRECTORS ASSISTS THE BOARD IN OVERSEEING COMPENSATION POLICIES AND BEST PRACTICES. RESPONSIBILITIES INCLUDE OVERSIGHT OF THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER; THE RANGE OF COMPENSATION LEVELS FOR THE ORGANIZATION'S OTHER OFFICERS, DISQUALIFIED PERSONS, AND OTHER KEY EMPLOYEES; GRANTING THE CHIEF EXECUTIVE OFFICER WITH THE AUTHORITY TO DETERMINE COMPENSATION LEVELS WITHIN AN APPROVED RANGE; AND ANY INCENTIVE/BONUS COMPENSATION PROGRAMS, IF APPROVED. THE CURRENT POLICY WAS ADOPTED IN 2010 AND IS REVIEWED ANNUALLY. A FORMAL COMPENSATION POLICY GOVERNS PAY PRACTICES. PERIODICALLY, ALL POSITIONS IN THE ORGANIZATION ARE REVIEWED AGAINST EXTERNAL MARKET DATA BY ENGAGING INDEPENDENT EXPERTS OR ACQUIRING UPDATED MARKET DATA TO CONDUCT THE BENCHMARKING PROCESS. COMPENSATION IS THEN BASED UPON COMPARABLE MARKET RATES OF PAY WITH CONSIDERATION FOR INTERNAL EQUITY AND THE FINANCIAL POSITION OF THE ORGANIZATION. BENCHMARKING WAS CONDUCTED FOR THE CHIEF EXECUTIVE OFFICER AND ALL EXECUTIVE TEAM MEMBERS' COMPENSATION TO EXTERNAL MARKET DATA IN 2022, TO ENSURE MARKET ALIGNMENT. KOMEN PROVIDES SALARY INCREASES, PROMOTIONS AND OTHER FORMS OF COMPENSATION WITHOUT REGARD TO RACE, COLOR, RELIGION, GENDER, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS OR SEXUAL ORIENTATION.
Form 990, Part VI, Line 15b Process to establish compensation of other employees	THE HUMAN CAPITAL MANAGEMENT COMMITTEE OF THE BOARD OF DIRECTORS ASSISTS THE BOARD IN OVERSEEING COMPENSATION POLICIES AND BEST PRACTICES. RESPONSIBILITIES INCLUDE OVERSIGHT OF THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER; THE RANGE OF COMPENSATION LEVELS FOR THE ORGANIZATION'S OTHER OFFICERS, DISQUALIFIED PERSONS, AND OTHER KEY EMPLOYEES; GRANTING THE CHIEF EXECUTIVE OFFICER WITH THE AUTHORITY TO DETERMINE COMPENSATION LEVELS WITHIN AN APPROVED RANGE; AND ANY INCENTIVE/BONUS COMPENSATION PROGRAMS, IF APPROVED. THE CURRENT POLICY WAS ADOPTED IN 2010 AND IS REVIEWED ANNUALLY. A FORMAL COMPENSATION POLICY GOVERNS PAY PRACTICES. PERIODICALLY, ALL POSITIONS IN THE ORGANIZATION ARE REVIEWED AGAINST EXTERNAL MARKET DATA BY ENGAGING INDEPENDENT EXPERTS OR ACQUIRING UPDATED MARKET DATA TO CONDUCT THE BENCHMARKING PROCESS. COMPENSATION IS THEN BASED UPON COMPARABLE MARKET RATES OF PAY WITH CONSIDERATION FOR INTERNAL EQUITY AND THE FINANCIAL POSITION OF THE ORGANIZATION. BENCHMARKING WAS CONDUCTED FOR THE CHIEF EXECUTIVE OFFICER AND ALL EXECUTIVE TEAM MEMBERS' COMPENSATION TO EXTERNAL MARKET DATA IN 2022, TO ENSURE MARKET ALIGNMENT. KOMEN PROVIDES SALARY INCREASES, PROMOTIONS AND OTHER FORMS OF COMPENSATION WITHOUT REGARD TO RACE, COLOR, RELIGION, GENDER, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS OR SEXUAL ORIENTATION.
Form 990, Part VI, Line 19 Required documents available to the public	KOMEN'S FINANCIAL STATEMENTS AND THE FORM 990 ARE PUBLICLY AVAILABLE ON OUR WEBSITE. THE CERTIFICATE OF FORMATION IS AVAILABLE FROM THE TEXAS SECRETARY OF STATE AND OTHER GOVERNING DOCUMENTS ARE MADE AVAILABLE AS REQUIRED BY STATE LAW. FORM 1023 AND THE CONFLICT OF INTEREST POLICY ARE NOT PUBLISHED ONLINE BUT ARE AVAILABLE TO THE PUBLIC UPON REQUEST.
Form 990, Part IX, Line 1	FOR NEARLY 40 YEARS, SUSAN G. KOMEN HAS WORKED TO FULFILL ITS VISION OF CREATING A WORLD WITHOUT BREAST CANCER THROUGH ITS MISSION OF SAVING LIVES BY MEETING THE MOST CRITICAL NEEDS IN OUR COMMUNITIES AND INVESTING IN BREAKTHROUGH RESEARCH TO BETTER DETECT, PREVENT, TREAT BREAST CANCERS. OVER THE LAST TWO YEARS, KOMEN CONTINUED TO IMPLEMENT A SERIES OF CHANGES BEGUN IN 2020 TO STRENGTHEN ITS FINANCIAL AND OPERATIONAL POSITION IN RESPONSE TO THE CHANGING NEEDS OF THE BREAST CANCER COMMUNITY AND ECONOMIC CONDITIONS RESULTING FROM THE COVID-19 PANDEMIC. KOMEN HAS NEARLY COMPLETED THE CONSOLIDATION OF ALL OPERATIONS OF ITS INDEPENDENT AFFILIATES INTO ITS HEADQUARTERS ORGANIZATION, RESULTING IN A SINGLE ORGANIZATION. THIS CONSOLIDATION IS ENABLING KOMEN TO LEVERAGE THE COMBINED EXPERTISE OF ITS MISSION LEADERS TO DELIVER A UNITED MISSION PROGRAM, UTILIZING TECHNOLOGY AS A KEY DRIVER TO CONNECT TO PEOPLE WHO NEED TO ACCESS CARE WHERE THEY ARE AND TO HELP IMPROVE THE PATIENT EXPERIENCE, AS WELL AS RESULTED IN ADMINISTRATIVE AND OPERATIONAL EFFICIENCIES. CENTRAL TO KOMEN'S VISION IS A STEADFAST COMMITMENT TO INVESTING IN BREAKTHROUGH RESEARCH. KOMEN REMAINED COMMITTED TO INVESTING IN RESEARCH FOCUSED ON ITS PRIMARY FOCUS ON METASTATIC BREAST CANCER AND UNDERSTANDING AND ELIMINATING DISPARITIES IN BREAST CANCER OUTCOMES BETWEEN BLACK AND WHITE PATIENTS. DESPITE THE ECONOMIC UNCERTAINTY AND CHALLENGING FUNDRAISING ENVIRONMENT, KOMEN AWARDED $21 MILLION IN NEW RESEARCH AWARDS. WHILE WE CONTINUE TO INVEST IN RESEARCH INTO NEW TREATMENTS, KOMEN SUPPORTS PEOPLE WHO ARE FACING BREAST CANCER TODAY THROUGH A GROWING SUITE OF PATIENT CARE SERVICES, INCLUDING DIRECT FINANCIAL ASSISTANCE THROUGH ITS TREATMENT ASSISTANCE PROGRAM, ELIGIBLE TO HELP PAY FOR EXPENSES THAT MAY SERVE AS A BARRIER TO ATTAINING THE CARE NEEDED TO SURVIVE, SUCH AS CO-PAYS, TRANSPORTATION, CHILDCARE OR RENT.
Form 990, Part XI, Line 9 Other changes in net assets or fund balances	RESCINDED GRANTS - 589946; Event Cost Reclass - 27703;